Steven Rosenberg
#8,944
Most Influential Person Now
American cancer researcher
Steven Rosenberg's AcademicInfluence.com Rankings
Steven Rosenbergbiology Degrees
Biology
#368
World Rank
#654
Historical Rank
#215
USA Rank
Molecular Biology
#42
World Rank
#42
Historical Rank
#30
USA Rank
Download Badge
Biology
Steven Rosenberg's Degrees
- Bachelors Biology University of California, Berkeley
- PhD Molecular Biology Stanford University
Similar Degrees You Can Earn
Why Is Steven Rosenberg Influential?
(Suggest an Edit or Addition)According to Wikipedia, Steven A. Rosenberg is an American cancer researcher and surgeon, chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He pioneered the development of immunotherapy that has resulted in the first effective immunotherapies and the development of gene therapy. He is the first researcher to successfully insert foreign genes into humans.
Steven Rosenberg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cancer : Principles and Practice of Oncology (1982) (7969)
- Cancer immunotherapy: moving beyond current vaccines (2004) (2944)
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2002) (2901)
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (2003) (2799)
- A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. (1987) (2783)
- Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006) (2575)
- Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. (1985) (2506)
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial (2015) (2318)
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes (1982) (2143)
- Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. (1988) (2109)
- Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. (2010) (2053)
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (1998) (1897)
- High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. (1999) (1879)
- Adoptive cell transfer as personalized immunotherapy for human cancer (2015) (1767)
- A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. (1986) (1731)
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. (2005) (1640)
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (2003) (1591)
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy (2011) (1551)
- Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008) (1522)
- Adoptive immunotherapy for cancer: harnessing the T cell response (2012) (1487)
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) (1449)
- T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years (1995) (1412)
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. (2009) (1401)
- Progress in human tumour immunology and immunotherapy (2001) (1376)
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer (2014) (1367)
- Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. (1998) (1339)
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. (2009) (1338)
- Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. (2015) (1321)
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. (2012) (1306)
- Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. (2008) (1283)
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. (1995) (1249)
- Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. (1990) (1226)
- The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. (1982) (1188)
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (2010) (1174)
- Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. (1994) (1121)
- Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. (1994) (1118)
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (2006) (1088)
- Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells (2005) (998)
- Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients (1989) (995)
- Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. (1994) (983)
- Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells (2013) (979)
- Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. (2005) (969)
- Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. (1994) (964)
- LYMPHOSARCOMA: A REVIEW OF 1269 CASES (1961) (964)
- Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells (2003) (945)
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy (2013) (943)
- Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. (2005) (929)
- Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. (2005) (919)
- Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes (1994) (899)
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (2010) (888)
- Adoptive immunotherapy for cancer: building on success (2006) (872)
- IL-2: The First Effective Immunotherapy for Human Cancer (2014) (854)
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. (2016) (853)
- PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. (2014) (814)
- Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. (2003) (784)
- Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. (2006) (778)
- CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells (2005) (735)
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 (1985) (720)
- Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. (1984) (717)
- Risk of second cancers after treatment for Hodgkin's disease. (1988) (704)
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007) (679)
- Important advances in oncology (1991) (667)
- Identification of human cancers deficient in antigen processing (1993) (657)
- Adoptive-cell-transfer therapy for the treatment of patients with cancer (2003) (655)
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients (2016) (650)
- gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. (2011) (645)
- A new era for cancer immunotherapy based on the genes that encode cancer antigens. (1999) (636)
- Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients (2003) (628)
- Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. (1995) (621)
- Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. (1993) (615)
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade (2007) (612)
- Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. (1996) (610)
- In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. (1985) (600)
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response (2014) (592)
- IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. (2006) (588)
- Adoptive cell therapy for the treatment of patients with metastatic melanoma. (2009) (581)
- Immunogenicity of somatic mutations in human gastrointestinal cancers (2015) (575)
- Biological activity of recombinant human interleukin-2 produced in Escherichia coli. (1984) (572)
- Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes (1994) (571)
- A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes (1996) (565)
- Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. (2002) (564)
- IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells (2004) (553)
- Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. (1981) (548)
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. (2011) (547)
- Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. (1989) (547)
- Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. (1986) (546)
- Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. (2010) (544)
- High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. (2000) (542)
- Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. (1996) (516)
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (2018) (513)
- gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand (1998) (505)
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. (2013) (503)
- Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma (2005) (500)
- Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. (2015) (496)
- Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. (1987) (496)
- Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study (2005) (495)
- Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy (2004) (494)
- Exome sequencing identifies GRIN2A as frequently mutated in melanoma (2011) (493)
- High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. (1986) (488)
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells (1983) (477)
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. (2016) (468)
- Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. (2007) (465)
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma (2012) (462)
- The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. (1987) (457)
- TRANSPLANTATION IN MINIATURE SWINE: I. Fixation of the Major Histocompatibility Complex (1976) (452)
- Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. (2000) (449)
- Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. (2015) (448)
- Exploiting the curative potential of adoptive T‐cell therapy for cancer (2014) (444)
- Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer (2011) (438)
- Cancer vaccines based on the identification of genes encoding cancer regression antigens. (1997) (434)
- High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. (1999) (433)
- Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma (1997) (429)
- Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. (2006) (428)
- IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells (2006) (422)
- Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. (1999) (421)
- Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. (1999) (421)
- Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression (1995) (418)
- Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. (1985) (414)
- Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. (1998) (410)
- Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes (1991) (408)
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. (2017) (404)
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors (2013) (403)
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells (1983) (401)
- IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. (2008) (400)
- Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes (2004) (397)
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2 (1984) (391)
- Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma (2001) (379)
- Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. (1992) (377)
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression (2011) (372)
- Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity (2009) (369)
- Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. (1977) (369)
- A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma (2002) (368)
- In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. (1985) (365)
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma (2008) (362)
- Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. (1989) (361)
- Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. (1998) (360)
- Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. (1987) (358)
- Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 (2009) (358)
- Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. (1993) (357)
- Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. (1996) (355)
- The fate of interleukin-2 after in vivo administration. (1983) (355)
- Female Reproductive Potential after Treatment for Hodgkin's Disease (1981) (354)
- Clinical effects and toxicity of interleukin‐2 in patients with cancer (1986) (350)
- T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. (2011) (349)
- Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. (1979) (347)
- Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 (2005) (343)
- Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions (2014) (342)
- Quality of life assessment of patients in extremity sarcoma clinical trials. (1982) (339)
- Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. (2005) (338)
- Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases (1997) (336)
- Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. (2007) (335)
- Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. (1998) (334)
- Patterns of recurrence in patients with high-grade soft-tissue sarcomas. (1985) (326)
- Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. (1989) (323)
- Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. (1988) (322)
- Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. (2001) (322)
- Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions (2008) (321)
- Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? (2006) (320)
- Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. (1999) (319)
- Biologic Therapy of Cancer (1992) (315)
- Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know (2011) (314)
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor (2009) (314)
- Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. (1984) (309)
- 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations (2017) (309)
- Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. (1991) (306)
- Human tumor antigens for cancer vaccine development (1999) (305)
- The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. (1985) (304)
- Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma (2005) (304)
- Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 (2006) (303)
- IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. (2011) (299)
- Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. (2005) (299)
- Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. (1994) (298)
- Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. (1994) (297)
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. (2010) (296)
- Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. (2015) (294)
- Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia (2013) (294)
- Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. (1987) (294)
- Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes (1996) (290)
- CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma (2010) (289)
- Prospects for gene-engineered T cell immunotherapy for solid cancers (2016) (288)
- Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. (1999) (284)
- Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer (2017) (280)
- Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. (2012) (280)
- Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen (1996) (280)
- In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. (1995) (278)
- In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. (1980) (276)
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1 (2009) (275)
- Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. (2011) (272)
- High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. (2006) (269)
- Immunotherapy and gene therapy of cancer. (1991) (269)
- Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. (2002) (265)
- The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. (1982) (264)
- Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. (1994) (263)
- High‐grade soft tissue sarcomas of the extremities (1986) (262)
- Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma (2006) (262)
- Immunotherapy of cancer using interleukin 2: current status and future prospects. (1988) (261)
- Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. (2015) (260)
- In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. (1987) (259)
- Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. (1996) (259)
- High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens (2003) (259)
- Antigen processing in vivo and the elicitation of primary CTL responses. (1995) (257)
- Passive immunotherapy of cancer in animals and man. (1977) (257)
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. (2016) (255)
- Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma (2015) (255)
- Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. (1978) (253)
- Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. (1985) (251)
- Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain (1993) (247)
- Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. (1988) (246)
- EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss (2013) (246)
- Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice (2011) (244)
- Antitumor activity of recombinant interleukin 6 in mice (1990) (243)
- Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. (1998) (241)
- Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. (1995) (240)
- Cardiorespiratory effects of immunotherapy with interleukin-2. (1989) (240)
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells (2010) (239)
- Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. (1996) (239)
- The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. (1980) (238)
- Raising the Bar: The Curative Potential of Human Cancer Immunotherapy (2012) (238)
- Treating cancer with genetically engineered T cells. (2011) (237)
- Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. (2005) (237)
- Two hundred years of cancer research. (2012) (236)
- Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. (2010) (234)
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice (2012) (233)
- Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. (1982) (233)
- Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy (2008) (231)
- No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. (1979) (230)
- Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. (2011) (229)
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines (2008) (226)
- Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261] (1995) (225)
- A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. (1998) (224)
- Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. (1997) (222)
- Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. (1987) (221)
- Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes (1996) (220)
- CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production (2001) (217)
- AIDS: Etiology, Diagnosis, Treatment, and Prevention (1992) (215)
- Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. (1985) (214)
- Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade (2005) (214)
- Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression (2004) (213)
- Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. (1996) (213)
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes (1986) (212)
- Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. (2007) (212)
- Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. (2017) (210)
- Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. (2010) (209)
- Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. (1979) (208)
- NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. (1988) (207)
- Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. (1978) (207)
- Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. (1997) (207)
- Localization of 111Indium‐labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response (1994) (206)
- Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy (2005) (206)
- Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). (1998) (202)
- IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. (1989) (201)
- High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines1 (2007) (201)
- Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines (2005) (199)
- In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. (1989) (194)
- Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. (1991) (194)
- Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. (1999) (194)
- Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression (2005) (193)
- Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. (1991) (192)
- Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. (2013) (192)
- Metabolic imaging of human extremity musculoskeletal tumors by PET. (1988) (191)
- Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. (1998) (191)
- Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. (1995) (191)
- Trends in the safety of high dose bolus interleukin‐2 administration in patients with metastatic cancer (1998) (190)
- The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. (1981) (189)
- Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer (2020) (186)
- Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. (2018) (186)
- Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. (1995) (183)
- Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. (1996) (183)
- Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. (1988) (181)
- Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100 (2000) (181)
- Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. (2012) (180)
- Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma (2019) (180)
- Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells (1999) (179)
- The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin‐2: A Review (1988) (179)
- Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities (1983) (177)
- Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. (1979) (177)
- A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability (1992) (176)
- Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. (1995) (176)
- TGF-β1 Attenuates the Acquisition and Expression of Effector Function by Tumor Antigen-Specific Human Memory CD8 T Cells (2005) (176)
- Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities. (1985) (174)
- Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. (1984) (174)
- Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo1 (2007) (174)
- Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. (1997) (173)
- T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy (2013) (172)
- Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition (2008) (172)
- Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. (2017) (172)
- Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. (2015) (172)
- Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial (2014) (170)
- Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo (1998) (169)
- Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. (1997) (169)
- Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma (1988) (168)
- Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. (1992) (166)
- Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. (1985) (166)
- RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. (1996) (166)
- Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. (2017) (166)
- Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. (1987) (165)
- Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1 (2001) (165)
- Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules (2000) (165)
- Evaluation of computed tomography in the detection of pulmonary metastases. A prospective study (1979) (165)
- Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. (1977) (165)
- Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells (2010) (165)
- Shedding light on immunotherapy for cancer. (2004) (164)
- Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. (1987) (164)
- A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. (1983) (164)
- Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. (1981) (162)
- Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. (2012) (162)
- In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. (1994) (162)
- Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy (2010) (161)
- Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers (2019) (161)
- Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. (1983) (161)
- Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. (1990) (160)
- Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. (2004) (160)
- Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. (2001) (160)
- Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. (1995) (160)
- Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. (1986) (159)
- CD4+CD25+ Suppressor Lymphocytes in the Circulation of Patients Immunized Against Melanoma Antigens (2003) (159)
- Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. (1996) (158)
- Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma (2009) (158)
- Metastasectomy for soft tissue sarcoma. Further evidence for efficacy and prognostic indicators. (1989) (157)
- A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer (2011) (157)
- TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients (2012) (156)
- Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. (1988) (155)
- Transplantation in miniature swine. (1977) (155)
- Adoptive immunotherapy of newly induced murine sarcomas. (1985) (154)
- Frequent mutations in the MITF pathway in melanoma (2009) (154)
- Complete axillary lymph node dissection for stage I-II carcinoma of the breast. (1986) (152)
- A novel approach to the generation and identification of experimental hepatic metastases in a murine model. (1986) (151)
- Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment (2014) (151)
- FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. (2008) (149)
- Human melanoma cells do not express Fas (Apo-1/CD95) ligand. (1999) (148)
- Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients (1985) (148)
- Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. (1996) (147)
- Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. (2018) (145)
- Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma (2013) (144)
- A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. (2014) (144)
- The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. (1987) (144)
- Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. (1985) (144)
- Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. (1989) (144)
- Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma (2011) (144)
- Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells (1999) (143)
- Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor (2016) (142)
- Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. (1987) (142)
- Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. (1996) (142)
- Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. (1996) (141)
- Human tumor antigens recognized by T-cells (1997) (140)
- Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. (1999) (140)
- IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. (1996) (140)
- Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy1 (2006) (140)
- In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. (1987) (140)
- Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma (2019) (139)
- Prognostic Factors in Patients Undergoing Lymphadenectomy of Malignant Melanoma (1977) (139)
- Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. (1991) (138)
- Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression (2013) (138)
- The neuroendocrine effects of interleukin-2 treatment. (1989) (138)
- Lymphocytes as cellular vehicles for gene therapy in mouse and man. (1991) (136)
- Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. (1993) (136)
- Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice (2000) (136)
- Dermatologic changes associated with interleukin 2 administration. (1987) (135)
- Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. (1993) (135)
- Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. (2019) (134)
- Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR (2005) (133)
- The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. (1984) (133)
- Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity (2008) (132)
- Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. (1986) (131)
- Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. (1978) (131)
- Lymphokine‐activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer (1985) (130)
- Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. (1986) (129)
- Bcl-2 overexpression enhances tumor-specific T-cell survival. (2005) (129)
- Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. (2008) (129)
- Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6 (2015) (129)
- Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. (1998) (129)
- Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. (1991) (129)
- A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers (2018) (128)
- Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. (1988) (128)
- In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. (1978) (128)
- Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells (2000) (127)
- The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. (1997) (127)
- IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. (1995) (127)
- Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. (1988) (127)
- Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. (1988) (126)
- Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials (2010) (126)
- Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity (2019) (126)
- Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. (2000) (126)
- Toll-like Receptors in Tumor Immunotherapy (2007) (126)
- Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. (2008) (126)
- In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. (1989) (125)
- Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. (1984) (125)
- Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. (2003) (124)
- Adoptive cell transfer therapy. (2007) (124)
- An antigenic peptide produced by reverse splicing and double asparagine deamidation (2011) (124)
- Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens (2016) (123)
- Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. (2002) (123)
- Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. (1988) (123)
- Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action (1990) (122)
- Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade” (2006) (122)
- Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. (1998) (122)
- mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. (2020) (122)
- Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length (2007) (121)
- CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 (2013) (121)
- Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. (1993) (121)
- Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. (1992) (121)
- Principles and Practice of the Biologic Therapy of Cancer (2000) (120)
- Murine epidermal Langerhans cells and splenic dendritic cells present tumor‐associated antigens to primed T cells (1994) (120)
- Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. (1998) (119)
- Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. (1986) (118)
- Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens (2003) (118)
- Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells (1984) (118)
- CARs on track in the clinic. (2011) (116)
- Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression (2016) (116)
- Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion1 (2006) (116)
- Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. (1981) (116)
- A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk (1985) (116)
- Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. (1999) (116)
- Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells (2009) (116)
- Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. (1989) (115)
- Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously Expressing Telomerase (2004) (115)
- Early Versus Delayed Shoulder Motion Following Axillary Dissection: A Randomized Prospective Study (1981) (115)
- Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. (2003) (114)
- Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. (1986) (114)
- The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. (1986) (113)
- Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. (1989) (113)
- Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. (1988) (113)
- In vitro growth of murine T cells. I. Production of factors necessary for T cell growth. (1978) (113)
- Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection (1987) (112)
- Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity (2001) (112)
- Magnetic Resonance Imaging Versus Computed Tomography in the Evaluation of Soft Tissue Tumors of the Extremities (1987) (112)
- Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. (1997) (112)
- Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. (1995) (111)
- Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. (2020) (111)
- Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. (1997) (110)
- Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy (1991) (110)
- Clinical course and management of accidental adriamycin extravasation (1977) (110)
- The Shedding of CD62L (L-Selectin) Regulates the Acquisition of Lytic Activity in Human Tumor Reactive T Lymphocytes (2011) (110)
- Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. (2007) (109)
- Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. (1999) (108)
- Immunotherapy of Human Cancer (1982) (108)
- IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. (1989) (108)
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response (1999) (108)
- Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. (2013) (108)
- Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells (2014) (107)
- Effects of fractionated irradiation of endocrine aspects of testicular function. (1985) (107)
- Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. (1982) (107)
- Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. (1997) (106)
- Cardiopulmonary toxicity of treatment with high dose interleukin‐2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma (1994) (106)
- Experimental and clinical studies with intraoperative radiotherapy. (1983) (106)
- T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product (2004) (104)
- Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL (2010) (104)
- implications for cancer therapy (1996) (104)
- Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. (1988) (104)
- Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules1 (2003) (104)
- Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. (1995) (103)
- Cutaneous malignant melanoma after Hodgkin's disease. (1985) (103)
- Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. (1987) (102)
- A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. (1986) (102)
- Cancer: Principles & Practice of Oncology: Annual Advances in Oncology (2012) (102)
- Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. (2006) (102)
- Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. (1981) (102)
- T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study (2019) (102)
- Selective stimulation of nonhistone chromatin protein synthesis in lymphoid cells by phytohemagglutinin. (1973) (101)
- Functional Heterogeneity of Vaccine-Induced CD8+ T Cells1 (2002) (101)
- Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. (1987) (99)
- High-dose aldesleukin in renal cell carcinoma: long-term survival update. (1997) (99)
- Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. (1996) (99)
- Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. (2003) (99)
- MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. (1999) (99)
- Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. (1993) (99)
- Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine1 (2005) (99)
- Adoptive Cell Therapy: Genetic Modification to Redirect Effector Cell Specificity (2010) (98)
- T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers (2018) (98)
- Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens (2016) (98)
- Growth of tumor‐infiltrating lymphocytes from human solid cancers: Summary of a 5‐year experience (1996) (98)
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade (2008) (98)
- Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. (1995) (98)
- Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. (1985) (98)
- Interleukin 2 and psoriasis. (1988) (98)
- Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. (2000) (98)
- Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment (2012) (97)
- Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. (2009) (97)
- The use of melanosomal proteins in the immunotherapy of melanoma. (1998) (97)
- Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. (2007) (97)
- Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression (2009) (96)
- Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. (1989) (96)
- Immunomodulators in Clinical Medicine (1987) (95)
- Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma (2012) (95)
- Adoptive T-Cell Therapy for Cancer. (2016) (95)
- In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. (1986) (94)
- Renal cell carcinoma: resection of solitary and multiple metastases. (1992) (94)
- The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. (1996) (94)
- Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. (1992) (94)
- NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis (2012) (94)
- Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination (2001) (93)
- Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity (2009) (93)
- Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation (2016) (93)
- Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. (1986) (93)
- Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells (1987) (93)
- Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain Metastases (2002) (92)
- Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. (1993) (92)
- Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells (1994) (92)
- Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. (1995) (92)
- Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. (1996) (92)
- Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness (1985) (91)
- Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. (1984) (91)
- Intraperitoneal administration of interleukin-2 in patients with cancer. (1986) (91)
- Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin‐2 Alone (1995) (91)
- Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes (2012) (91)
- Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity (2015) (91)
- Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy (2013) (90)
- Early lymphatic spread of osteogenic and soft-tissue sarcomas. (1978) (90)
- Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails (2013) (90)
- The effects of postoperative adjuvant chemotherapy and radiotherapy on testicular function in men undergoing treatment for soft tissue sarcoma (1981) (89)
- Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. (1996) (89)
- Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. (1987) (89)
- Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. (1986) (89)
- Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy (2012) (88)
- Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. (1988) (88)
- Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations. (1984) (88)
- Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. (2018) (88)
- Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. (1981) (88)
- A prospective evaluation of delta‐9‐tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy (1981) (87)
- Inhibition of leukocyte migration: an evaluation of this in vitro assay of delayed hypersensitivity in man to a soluble antigen. (1970) (86)
- Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. (1994) (86)
- Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma (2002) (86)
- Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. (1985) (85)
- Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. (1996) (85)
- Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer (2019) (85)
- Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting (2016) (85)
- Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies (2011) (85)
- Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. (2013) (84)
- Immunotherapy for metastatic solid cancers. (2011) (84)
- Systemic administration of recombinant human interleukin-2 in mice. (1984) (83)
- Recurrent inactivating RASA2 mutations in melanoma (2015) (83)
- Immunotherapy: The Path to Win the War on Cancer? (2015) (83)
- Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. (1988) (82)
- Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma (2016) (82)
- Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients (2019) (82)
- Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase (2010) (82)
- Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction (1991) (82)
- Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. (1986) (81)
- TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. (2005) (81)
- Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. (1990) (81)
- Important advances in oncology 1986 (1994) (81)
- Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. (1994) (81)
- Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. (2013) (80)
- Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor (2012) (80)
- Adoptive immunotherapy for cancer. (1990) (80)
- Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. (1996) (80)
- Systemic administration of interleukin-2 in humans. (1984) (79)
- Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. (2019) (79)
- Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. (1995) (78)
- Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. (1996) (77)
- Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium (2002) (77)
- Secrecy in medical research. (1996) (77)
- Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases (2000) (77)
- The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. (1992) (77)
- An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. (1997) (77)
- Impact of salvage treatment on initial relapses in patients with Hodgkin disease, stages I-III. (1978) (76)
- Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. (1982) (76)
- Sequential radiotherapy and chemotherapy in the treatment of Hodgkin's disease. A progress report. (1972) (76)
- Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2 (2006) (75)
- T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model (2008) (75)
- Pre-Existing Immunity to Tyrosinase-Related Protein (TRP)-2, a New TRP-2 Isoform, and the NY-ESO-1 Melanoma Antigen in a Patient with a Dramatic Response to Immunotherapy (2002) (75)
- Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. (1997) (75)
- Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. (1988) (75)
- Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. (1999) (75)
- Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes (2000) (74)
- Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma. (1991) (74)
- Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. (2015) (74)
- Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. (2015) (73)
- Separation and functional studies of the human lymphokine-activated killer cell. (1987) (73)
- The role of monocytes in pokeweed mitogen-stimulated human B cell activation: separate requirements for intact monocytes and a soluble monocyte factor. (1981) (73)
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. (2020) (73)
- Limb-sparing surgery for soft tissue sarcomas: wound related morbidity in patients undergoing wide local excision. (1987) (73)
- A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. (2010) (73)
- Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. (1986) (73)
- The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma (1995) (73)
- Adoptive immunotherapy of cancer: accomplishments and prospects. (1984) (73)
- Human gene marker/therapy clinical protocols. (1996) (73)
- Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma (2020) (72)
- Mobilization of Dendritic Cell Precursors in Patients With Cancer by Flt3 Ligand Allows the Generation of Higher Yields of Cultured Dendritic Cells (2002) (72)
- Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. (1989) (72)
- Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. (2009) (72)
- In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. (1980) (72)
- Isolation of a New Melanoma Antigen, MART-2, Containing a Mutated Epitope Recognized by Autologous Tumor-Infiltrating T Lymphocytes1 (2001) (71)
- Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration (2008) (71)
- Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors. (1990) (71)
- Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. (2011) (71)
- Hodgkin's disease in patients over sixty years old. (1984) (71)
- T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. (1994) (71)
- Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide Vaccination (2004) (70)
- Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. (1996) (70)
- Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. (1989) (70)
- Thyroid dysfunction associated with immunotherapy for patients with cancer (1991) (70)
- Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy (2010) (70)
- Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. (1985) (69)
- Serologic identification of multiple tumor-associated antigens on murine sarcomas. (1977) (69)
- The Development of Gene Therapy for the Treatment of Cancer (1993) (68)
- 24 Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma (2018) (68)
- Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. (1981) (68)
- Erratum: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer (J Natl Cancer Inst (1993) 85 (622-632)) (1993) (68)
- Developing recombinant and synthetic vaccines for the treatment of melanoma. (1999) (68)
- Prospective randomized study of the role of N‐acetyl cysteine in reversing doxorubicin‐induced cardiomyopathy (1982) (68)
- Delayed reactions to contrast media after interleukin-2 immunotherapy. (1992) (67)
- Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. (2022) (67)
- Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. (1990) (67)
- The gene therapy of cancer. (1992) (67)
- Characterization of postsplenectomy bacteremia among patients with and without lymphoma. (1972) (67)
- Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. (1987) (67)
- Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma (2003) (67)
- An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. (2018) (66)
- Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. (1998) (66)
- Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. (2009) (66)
- Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients. (1990) (65)
- A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12 (2000) (65)
- Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells. (1986) (65)
- Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells. (2001) (64)
- Prognostic factors in pathologic stage III Hodgkin's disease. (1982) (64)
- Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. (2010) (64)
- SIALIC ACIDS ON THE PLASMA MEMBRANE OF CULTURED HUMAN LYMPHOID CELLS (1972) (63)
- A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen (1998) (63)
- TRANSPLANTATION IN MINIATURE SWINE: VI. FACTORS INFLUENCING SURVIVAL OF RENAL ALLOGRAFTS (1979) (63)
- Perspectives on the role of surgery and radiation therapy in the treatment of soft tissue sarcomas of the extremities. (1981) (63)
- Lymphosarcoma in childhood. (1958) (63)
- Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin. (1983) (63)
- Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. (1996) (63)
- Kinetics of TCR Use in Response to Repeated Epitope-Specific Immunization (2001) (63)
- T-cell recognition of self peptides as tumor rejection antigens (1996) (62)
- Collapse of the tumor stroma is triggered by IL-12 induction of Fas. (2013) (62)
- In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens. (1978) (62)
- Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. (1989) (62)
- Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. (2000) (62)
- Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. (1988) (62)
- Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers (2022) (62)
- Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting Chemotherapy (2007) (62)
- Intralesional immunotherapy of melanoma with BCG. (1976) (62)
- Combination Cytokine Immunotherapy with Tumor Necrosis Factor α, Interleukin 2, and α-Interferon and Its Synergistic Antitumor Effects in Mice (1989) (61)
- T cell responses to Mls determinants are restricted by cross-reactive MHC determinants. (1985) (61)
- Extremity soft tissue sarcomas: Analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher‐grade sarcomas (1989) (61)
- THE SYNDROME OF DEHYDRATION, COMA AND SEVERE HYPERGLYCEMIA WITHOUT KETOSIS IN PATIENTS CONVALESCING FROM BURNS. (1965) (61)
- T-cell therapy at the threshold (2012) (61)
- Identification of BING-4 Cancer Antigen Translated From an Alternative Open Reading Frame of a Gene in the Extended MHC Class II Region Using Lymphocytes From a Patient With a Durable Complete Regression Following Immunotherapy (2002) (61)
- 2D TCR–pMHC–CD8 kinetics determines T‐cell responses in a self‐antigen‐specific TCR system (2014) (61)
- Development of effective immunotherapy for the treatment of patients with cancer. (2004) (61)
- Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. (1993) (61)
- Resection of recurrent pulmonary metastases in patients with soft-tissue sarcomas. (1986) (61)
- Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells (2004) (61)
- T-cell recognition of human melanoma antigens. (1993) (61)
- Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells (2005) (60)
- Late relapse among patients treated for Hodgkin's disease. (1985) (60)
- A phase I trial of intravenous interleukin-6 in patients with advanced cancer. (1994) (59)
- Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. (1993) (59)
- Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. (1993) (59)
- Intralymphatic Dendritic Cell Vaccination Induces Tumor Antigen–Specific, Skin-Homing T Lymphocytes (2006) (58)
- Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. (1995) (58)
- Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen (2004) (57)
- Human tumor antigens recognized by T lymphocytes: implications for cancer therapy (1996) (57)
- Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. (1996) (57)
- A Prospective Randomized Trial Evaluating Colloid Versus Crystalloid Resuscitation in the Treatment of the Vascular Leak Syndrome Associated with Interleukin‐2 Therapy (1994) (57)
- IN VIVO ADMINISTRATION OF INTERLEUKIN‐2 ENHANCES SPECIFIC ALLOIMMUNE RESPONSES (1983) (57)
- The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone (2009) (57)
- Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. (1986) (56)
- Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. (1987) (56)
- Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy (2013) (56)
- Selective Growth, In Vitro and In Vivo, of Individual T Cell Clones from Tumor-Infiltrating Lymphocytes Obtained from Patients with Melanoma (2004) (55)
- Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients (2013) (55)
- In vivo administration of purified Jurkat-derived interleukin 2 in mice. (1984) (55)
- The Stoichiometric Production of IL-2 and IFN-γ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans (2012) (55)
- CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. (2006) (55)
- MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. (2010) (54)
- Methotrexate and hemodialysis. (1977) (54)
- New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer (2012) (54)
- Interleukin 2 for patients with renal cancer (2007) (54)
- MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases (2016) (54)
- T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. (2000) (54)
- Mechanism of action of Cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas. (1984) (54)
- IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis. (1990) (53)
- A monoclonal antibody that identifies human peripheral blood monocytes recognizes the accessory- cells required for mitogen-induced T lymphocyte proliferation. (1981) (53)
- Soft tissue sarcoma: functional outcome after wide local excision and radiation therapy. (1984) (53)
- Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy (2013) (53)
- Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy (1979) (52)
- IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. (2010) (52)
- Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. (1999) (52)
- Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review. (1989) (52)
- Overcoming obstacles to the effective immunotherapy of human cancer (2008) (52)
- A Prospective Analysis of Positron Emission Tomography and Conventional Imaging for Detection of Stage IV Metastatic Melanoma in Patients Undergoing Metastasectomy (2004) (52)
- Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. (1993) (51)
- MALIGNANCIES IN THE AIDS PATIENT: NATURAL HISTORY, TREATMENT STRATEGIES, AND PRELIMINARY RESULTS (1984) (51)
- Human gene marker/therapy clinical protocols. (1999) (51)
- Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. (2016) (51)
- Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens (2020) (50)
- Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? (2012) (50)
- CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. (1994) (50)
- The development of new cancer therapies based on the molecular identification of cancer regression antigens. (1995) (50)
- Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. (1993) (50)
- Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. (2007) (50)
- IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. (1989) (49)
- In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. (1981) (49)
- A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma (2016) (49)
- Patients With Melanoma Metastases at Cutaneous and Subcutaneous Sites Are Highly Susceptible to Interleukin-2–Based Therapy (2001) (49)
- Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. (1982) (49)
- Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution (2001) (49)
- Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Driver in Melanoma (2010) (49)
- IL-2 and IL-15 Each Mediate De Novo Induction of FOXP3 Expression in Human Tumor Antigen-specific CD8 T Cells (2007) (49)
- HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. (1992) (48)
- Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression. (1986) (48)
- Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis (1979) (47)
- The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2 (2004) (47)
- Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer (2004) (47)
- Combined modality treatment of adult soft tissue sarcomas of the head and neck. (1987) (47)
- T-cell immunotherapy: looking forward. (2014) (47)
- A highly recurrent RPS27 5'UTR mutation in melanoma (2014) (47)
- Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. (1990) (47)
- Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma (2006) (47)
- The hematologic toxicity of interleukin‐2 in patients with metastatic melanoma and renal cell carcinoma (1995) (47)
- A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma (2004) (46)
- Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples (2005) (46)
- Overview of interleukin-2 as an immunotherapeutic agent. (1989) (46)
- Immunotherapy and gene therapy of cancer. (1991) (46)
- Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. (1999) (46)
- The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. (1994) (46)
- Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin‐2‐based immunotherapy (1992) (46)
- Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate (1978) (45)
- T‐Cell Receptor Repertoire in Tumor‐Infiltrating Lymphocytes. Analysis of Melanoma‐Specific Long‐Term Lines (1994) (45)
- Comparison of Common γ-Chain Cytokines, Interleukin-2, Interleukin-7, and Interleukin-15 for the In Vitro Generation of Human Tumor-Reactive T Lymphocytes for Adoptive Cell Transfer Therapy (2006) (45)
- High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D (2020) (45)
- Myocarditis or acute myocardial infarction associated with interleukin‐2 therapy for cancer (1990) (45)
- In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (2011) (45)
- Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. (1998) (45)
- A simplified method for the production of murine T-cell growth factor free of lectin. (1981) (45)
- Incidence, recovery, and management of serratus anterior muscle palsy after axillary node dissection. (1983) (44)
- Lymphosarcoma: the effects of therapy and survival in 1,269 patients in a review of 30 years' experience. (1960) (44)
- Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice. (1991) (43)
- Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia (2015) (43)
- The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. (1986) (43)
- Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. (1995) (43)
- A new era of cancer immunotherapy: Converting theory to performance (1999) (43)
- Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. (1989) (43)
- Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. (1989) (43)
- Lymphokine-Activated Killer Cells (1989) (43)
- Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. (1998) (43)
- Surgical management of melanoma brain metastases in patients treated with immunotherapy. (2011) (43)
- In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. (1990) (43)
- Prospective randomized trials demonstrating the efficacy of adjuvant chemotherapy in adult patients with soft tissue sarcomas. (1984) (42)
- Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. (1986) (42)
- A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies. (2016) (42)
- Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010) (2005) (42)
- Clinical and immunologic studies of disseminated BCG infection (1978) (42)
- Human melanoma antigens recognized by T lymphocytes. (1996) (42)
- The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. (2002) (42)
- Clinical-scale Lentiviral Vector Transduction of PBL for TCR Gene Therapy and Potential for Expression in Less-differentiated Cells (2008) (41)
- Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. (1987) (41)
- Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. (1995) (41)
- Loss of S100 antigenicity in metastatic melanoma. (2005) (41)
- In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor. (1981) (41)
- Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies. (1984) (41)
- Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans (2014) (41)
- Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers (2016) (41)
- Subdiaphragmatic Hodgkin's disease: laparotomy and treatment results in 49 patients. (1987) (41)
- Specific Increase in Potency via Structure-Based Design of a TCR (2014) (40)
- Long-term outcome in 87 patients with low-grade soft-tissue sarcoma. (1993) (40)
- Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. (2008) (40)
- Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans. (1990) (40)
- Surgery for adult patients with soft tissue sarcomas. (1989) (40)
- Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. (2000) (39)
- Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. (2009) (39)
- Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2). (1993) (39)
- Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. (2008) (39)
- Transplantation in miniature swine. III: effects of MSLA and A-O blood group matching on skin allograft survival. (1978) (39)
- Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s). (1985) (39)
- CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion (2005) (38)
- The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha. (1989) (38)
- Melanoma NOS1 expression promotes dysfunctional IFN signaling. (2014) (38)
- Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. (1993) (38)
- Aggressive pulmonary resection for metastatic osteogenic and soft tissue sarcomas. (1984) (38)
- The toxicity of recombinant human interleukin-2 in rats following intravenous infusion. (1987) (38)
- Natural human antibodies to "hidden" membrane components. (1972) (37)
- IRF5 gene polymorphisms in melanoma (2012) (37)
- DeVita, Hellman, and Rosenberg's cancer : (2013) (37)
- Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. (1986) (37)
- Frequency of MART-1/MelanA and gp100/PMel17-Specific T Cells in Tumor Metastases and Cultured Tumor-Infiltrating Lymphocytes (2002) (37)
- Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes. (1991) (36)
- Interleukin-2–Independent Proliferation of Human Melanoma-Reactive T Lymphocytes Transduced With an Exogenous IL-2 Gene Is Stimulation Dependent (2003) (36)
- A Simplified Method for the Clinical-scale Generation of Central Memory-like CD8+ T Cells After Transduction With Lentiviral Vectors Encoding Antitumor Antigen T-cell Receptors (2010) (36)
- Surgical treatment of metastatic cancer (1987) (36)
- Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. (1993) (36)
- Cancer immunotherapy. (2008) (36)
- A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. (1992) (36)
- Prednisone in MOPP chemotherapy for Hodgkin's disease. (1976) (35)
- Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. (1994) (35)
- Analysis of the disintegrin‐metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma (2011) (35)
- Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion (2010) (35)
- An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. (1990) (34)
- Identification of cancer antigens: impact on development of cancer immunotherapies. (2000) (34)
- In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. (1987) (34)
- Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts. (1988) (34)
- Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines (2006) (34)
- Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. (1990) (34)
- Phenotypic characterization of murine tumor-infiltrating T lymphocytes. (1991) (34)
- Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma (2012) (33)
- Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes (2022) (33)
- Adhesion of tumour-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis. (1997) (33)
- Colonic perforation: An unusual complication of therapy with high‐dose lnterleukin‐2 (1988) (33)
- Immunoprophylaxis of methylcholanthrene-induced tumors in mice with Bacillus Calmette-Guérin and methanol-extracted residue. (1973) (33)
- In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in vitro sensitization with partially purified T-cell growth factor. (1982) (33)
- Melanoma-Reactive CD8 + T Cells Recognize a Novel Tumor Antigen Expressed in a Wide Variety of Tumor Types (2001) (33)
- Irradiation Enhances Human T-cell Function by Upregulating CD70 Expression on Antigen-presenting Cells In Vitro (2011) (33)
- LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. (2017) (32)
- A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people (2004) (32)
- Cancer immunotherapy comes of age (2005) (32)
- Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. (1982) (32)
- Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity. (1993) (32)
- Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. (1998) (32)
- In vitro growth of murine T cells. IV. Use of T-cell growth factor to clone lymphoid cells. (1980) (32)
- Stage IIB Hodgkin's disease: the Stanford experience. (1986) (31)
- Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. (1987) (31)
- Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. (1981) (31)
- Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. (2013) (31)
- Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. (1990) (31)
- Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. (1988) (31)
- The effect of combined modality therapy on local control and survival. (1986) (31)
- Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute. (1993) (31)
- The treatment of malignant histiocytosis. (1984) (31)
- Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer (2019) (31)
- Evaluation of &ggr;-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application (2012) (31)
- cancer patients regulatory T cells in + Foxp 3 hiCD 25 + IL-2 administration increases CD 4 (2006) (30)
- Presentation of Tumor Antigens by Dendritic Cells Genetically Modified With Viral and Nonviral Vectors (2006) (30)
- Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks. (1990) (30)
- TRANSPLANTATION IN MINIATURE SWINE: II. In Vitro Parameters of Histocompatibility in MSLA Homozygous Minipigs (1977) (30)
- Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study. (1990) (30)
- Adjuvant chemotherapy for treatment of extremity soft tissue sarcomas: Review of National Cancer Institute experience (1985) (30)
- Melanocyte Lineage-specific Antigen gpl00 Is Recognized by Melanoma-derived Tumor-infiltrating Lymphocytes By Alexander B. H. Bakker, Marco W. J. Schreurs, (1994) (30)
- Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010 (Cancer Research (2011) 71, (3175-3181)) (2011) (30)
- Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: Analysis by cytokine secretion (2005) (30)
- Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans. (1988) (30)
- Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. (2014) (30)
- Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases (2018) (30)
- Application of the Granzyme B ELISPOT Assay for Monitoring Cancer Vaccine Trials (2006) (30)
- HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. (2014) (29)
- Cytokine Regulation of Tumor Necrosis Factor-α and -β (Lymphotoxin)-Messenger RNA Expression in Human Peripheral Blood Mononuclear Cells (1990) (29)
- Transduction of an HLA-DP4–restricted NY-ESO-1–specific TCR into Primary Human CD4+ Lymphocytes (2006) (29)
- Anti‐Tumor Activity of Cytotoxic T Lymphocytes Elicited with Recombinant and Synthetic Forms of a Model Tumor‐Associated Antigen (1995) (29)
- Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. (2003) (29)
- Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. (2013) (29)
- Studies of serum-free culture medium in the generation of lymphokine activated killer cells. (1987) (29)
- Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation (2014) (29)
- Intellectually handicapped mothers: problems and prospects. (1982) (29)
- Procollagens as markers for the cell of origin of human bone tumors. (1980) (28)
- Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice. (1986) (28)
- Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer (2017) (28)
- Prevention of Interleukin-2 Withdrawal-Induced Apoptosis in Lymphocytes Retrovirally Cotransduced With Genes Encoding an Antitumor T-cell Receptor and an Antiapoptotic Protein (2010) (28)
- Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy (2009) (28)
- Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. (1995) (28)
- Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL. (1992) (28)
- Why perform sentinel-lymph-node biopsy in patients with melanoma? (2008) (28)
- Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma (2011) (28)
- Finding suitable targets is the major obstacle to cancer gene therapy (2014) (28)
- A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers. (2017) (27)
- Current approaches to the adoptive immunotherapy of cancer. (1988) (27)
- Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2. (1985) (27)
- Different Adjuvanticity of Incomplete Freund's Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine (2010) (27)
- Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma (2014) (27)
- Guinea pig lymphotoxin (LT). II. Physicochemical properties of LT produced by lymphocytes stimulated with antigen or concanavalin A: its differentiation from migration-inhibitory factor (MIF). (1973) (27)
- Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. (2002) (27)
- Response Rates of Patients With Metastatic Melanoma to High-Dose Intravenous Interleukin-2 After Prior Exposure to Alpha-Interferon or Low-Dose Interleukin-2 (2002) (26)
- Advantages of cryoperserved lymphocytes for sequential evaluation of human immune competence. I. Mitogen stimulation. (1977) (26)
- In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. (1992) (26)
- Mutational and Functional Analysis of the Tumor‐Suppressor PTPRD in Human Melanoma (2014) (26)
- Serologic analysis of human cancer antigens (1980) (26)
- Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients (2017) (26)
- Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1 (2003) (26)
- Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen. (2001) (26)
- Second cancers after radiotherapy for Hodgkin's disease. (1988) (26)
- Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. (2014) (26)
- 5 – Production and Properties of Human IL-2 (1982) (26)
- Synthesis of nuclear-associated proteins by lymphocytes within minutes after contact with phytohemagglutinin. (1972) (26)
- Novel somatic mutations in heterotrimeric G proteins in melanoma (2010) (26)
- Use of standard criteria for assessment of cancer vaccines. (2005) (25)
- Cellular immunotherapy of cancer (1990) (25)
- Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. (1994) (25)
- Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. (1990) (25)
- In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. (1992) (25)
- Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. (1983) (25)
- Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma (2016) (25)
- Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor. (1991) (24)
- Comprar DeVita. Cancer: Principles and Practice of Oncology , 9/e | Steven A. Rosenberg | 9781451118131 | Lippincott Williams & Wilkins (2011) (24)
- Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase (2001) (24)
- In Vivo Proliferation of Adoptively Transferred Tumor‐Infiltrating Lymphocytes in Mice (1991) (24)
- Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. (1990) (24)
- Identification of tumor-regression antigens in melanoma. (1996) (24)
- Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy (2019) (24)
- Guinea pig lymphotoxin (LT). I. In vitro studies of LT produced in response to antigen stimulation of lymphocytes. (1973) (24)
- A rapid microassay of cellular immunity in the guinea pig and mouse. (1972) (24)
- A Novel Murine T-Cell Receptor Targeting NY-ESO-1 (2014) (24)
- The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. (1986) (24)
- The role of monocyte factors in the differentiation of immunoglobulin secreting cells from human peripheral blood B cells. (1980) (24)
- Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade (2020) (23)
- A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. (2022) (23)
- Cross-reacting antigens in chemically induced sarcomas are fetal determinants. (1977) (23)
- Recognition of Shared Melanoma Antigens by Human Tumor-Infiltrating Lymphocytes (1992) (23)
- Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2. (1989) (23)
- Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma. (2010) (23)
- In vitro growth of murine T cells. III. Method for separation of T cell growth factor (TCGF) from concanavalin A and biological activity of the resulting TCGF. (1980) (23)
- Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy (2016) (22)
- Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models (2020) (22)
- Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer (2014) (22)
- Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes (1994) (22)
- Tumor-infiltrating lymphocytes from nonrenal urological malignancies (2005) (22)
- Early detection of lymphocyte stimulation and mixed lymphocyte interaction in man with a semimicro protein synthesis assay. (1974) (22)
- Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. (1987) (22)
- Characterization of IL-2-induced murine cells which exhibit ADCC activity. (1988) (22)
- Comprar Cancer: Principles & Practice of Oncology, 2ª Ed. Primer Of The Molecular Biology Of Cancer | Vincent T. DeVita Jr. | 9781496310637 | Lippincott Williams & Wilkins (2015) (22)
- Identification and characterization of a tumor infiltrating CD56+/CD16− NK cell subset with specificity for pancreatic and prostate cancer cell lines (2010) (22)
- Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD 8 + T cells (2007) (22)
- Structure-Based Design of Altered MHC Class II–Restricted Peptide Ligands with Heterogeneous Immunogenicity (2013) (22)
- Somatic mutations in MAP3K5 attenuate its pro-apoptotic function in melanoma through increased binding to Thioredoxin (2013) (22)
- Keynote address: perspectives on the use of interleukin-2 in cancer treatment. (1997) (21)
- Chimeric antigen receptor-modified T cells in CLL. (2011) (21)
- Spontaneous regression of hepatic metastases from gastric carcinoma (1972) (21)
- Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. (1988) (21)
- Helper T Cells Infiltrating Human Renal Cell Carcinomas Have the Phenotype of Activated Memory‐Like T Lymphocytes (1995) (20)
- Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement (2011) (20)
- Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. (1995) (20)
- Use of a continuous‐flow cell separator in density gradient isolation of lymphocytes (1987) (20)
- No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma. (2009) (20)
- Inhibition of pokeweed mitogen-induced immunoglobulin production in humans by gold compounds. (1979) (20)
- The early stimulation of protein synthesis in sensitized guinea pig lymph node cells by antigen. (1972) (20)
- Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma? (2014) (20)
- Staging Laparotomy in the Treatment of Metastatic Melanoma of the Lower Extremities (1975) (20)
- Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. (2009) (20)
- Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor (2008) (20)
- Expression of fetal antigens by normal human skin cells grown in tissue culture. (1977) (20)
- The malignant melanoma of hamsters. I. Pathologic characteristics of a transplanted melanotic and amelanotic tumor. (1961) (20)
- Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience (2018) (20)
- Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization (1983) (20)
- Induction of CD4+ Th1 Lymphocytes That Recognize Known and Novel Class II MHC Restricted Epitopes from the Melanoma Antigen gp100 by Stimulation with Recombinant Protein (2004) (20)
- Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma (2021) (20)
- A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types (2021) (20)
- Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration (2014) (19)
- Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes. (1995) (19)
- Progress in Oncology (2001) (19)
- Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. (1999) (19)
- Advantages of cryopreserved lymphocytes for sequential evaluation of human immune competence. II. Mixed lymphocyte cultures and mononuclear cell subpopulations. (1978) (19)
- Changes in laboratory results for cancer patients treated with interleukin-2. (1990) (19)
- T-Cell Transfer Therapy Targeting Mutant KRAS. (2017) (19)
- A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. (1994) (19)
- A rapid assay of cell mediated immunity to soluble antigens based on the stimulation of protein synthesis. (1972) (19)
- Combined effects of interferon α and interleukin 2 on the induction of a vascular leak syndrome in mice (2004) (19)
- CLONAL ANALYSIS OF THE LYMPHOID CELLS MEDIATING SKIN ALLOGRAFT REJECTION (1983) (19)
- Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide (1994) (19)
- Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. (1990) (19)
- Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor (1982) (19)
- Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer. (1988) (18)
- New opportunities for the development of cancer immunotherapies. (1998) (18)
- A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. (1997) (18)
- CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion (2005) (18)
- Route of immunization and the therapeutic impact of recombinant anticancer vaccines. (1997) (18)
- Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo. (1986) (18)
- COMPARISON OF COMPUTED AND CONVENTIONAL WHOLE LUNG TOMOGRAPHY IN THE DETECTION OF PULMONARY METASTASES (1977) (18)
- Adjuvant chemotherapy for patients with soft tissue sarcomas. (1981) (18)
- Antitumor effect of recombinant tumor necrosis factor-α against murine sarcomas at visceral sites: tumor size influences the response to therapy (1988) (18)
- Mutational Signatures of De-Differentiation in Functional Non-Coding Regions of Melanoma Genomes (2012) (17)
- Split thickness skin grafting of the plantar surface of the foot after wide excision of neoplasms of the skin. (1979) (17)
- T CELL DEPLETION OF HUMAN BONE MARROW USING MONOCLONAL ANTIBODY AND COMPLEMENT‐MEDIATED LYSIS (1983) (17)
- Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing (2021) (17)
- T-cell therapy against cancer mutations (2014) (17)
- Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation (2014) (17)
- Paraneoplastic granulocytosis in metastatic melanoma (2010) (17)
- Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. (2016) (17)
- Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. (1997) (17)
- Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. (1985) (17)
- A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells (2016) (17)
- Pulmonary granulomas induced by BCG (1978) (17)
- Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma. (1982) (17)
- Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. (1986) (17)
- Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment. (1991) (16)
- Current Stanford clinical trials for Hodgkin's disease. (1989) (16)
- Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors. (1987) (16)
- The Role of Glycogen Synthase Kinase 3 in Regulating IFN-b–Mediated IL-10 Production (2010) (16)
- Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma (2004) (16)
- The Use of Gene‐Modified Tumor‐Infiltrating Lymphocytes for Cancer Therapy (1994) (16)
- The persistence of human peripheral lymphocytes, tumor infiltrating lymphocytes, and colon adenocarcinomas in immunodeficient mice. (1992) (16)
- Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells. (2011) (16)
- Harvest of human bone marrow directly from bone. (1984) (16)
- RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2018) (16)
- Abstract LB-175: Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 (2010) (16)
- Retroviral transduction of interferon-γ cDNA into a nonimmunogenic murinefibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor (1993) (16)
- Parathyroid Hormone-Related Protein and Hypercalcemia in Patients With Metastatic Melanoma: Case Report and Review (2003) (16)
- Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. (1993) (16)
- Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell. (1987) (16)
- The Use of Congenitally Immunodeficient Mice to Study Human Tumor Metastases and Immunotherapy (1992) (16)
- Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma (2011) (16)
- Comparison of multiple assays for detecting human antibodies directed against surface antigens on normal and malignant human tissue culture cells. (1977) (16)
- Disseminated human malignant melanoma in congenitally immune-deficient (bg/nu/xid) mice. (1991) (16)
- Severe thrombocytopenia following intralesional BCG therapy (1978) (16)
- Localization of the MAGE1 gene encoding a human melanoma antigen to chromosome Xq28. (1994) (15)
- Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. (1998) (15)
- High‐Dose Oral and Intravenous Metoclopramide in Doxorubicin/Cyclophosphamide‐Induced Emesis A Randomized Double‐Blind Study (1987) (15)
- Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy (2015) (15)
- Serologic analysis of human tumor antigens. I. Antisarcoma antibodies in the sera of patients with osteogenic sarcomas. (1979) (15)
- Immunotherapy of advanced cancer. (1987) (15)
- Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2013) (15)
- The identification of cancer antigens: impact on the development of cancer vaccines. (2000) (15)
- The lymphokine-activated killer cell phenomenon: In vitro and in vivo studies (1982) (15)
- Laser Scanning Cytometry Evaluation of MART-1, gp100, and HLA-A2 Expression in Melanoma Metastases (2001) (15)
- Combination therapy with interferon-γ and interleukin-2 for the treatment of metastatic melanoma (1996) (15)
- Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells (2020) (14)
- Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors. (1995) (14)
- In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice. (1990) (14)
- Chemotherapy of the non-Hodgkin's lymphomas: the Stanford experience. (1977) (14)
- Clinical application of IL6 in cancer therapy. (1992) (14)
- Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? (1999) (14)
- The transformed cell : unlocking the mysteries of cancer (1993) (14)
- Original article: The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease (1992) (14)
- T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013. (2014) (14)
- Prospective evaluation of doxorubicin‐induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas (2006) (14)
- Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry. (1992) (14)
- Osteosarcoma cells in tissue culture: II. Characterization and localization of alkaline phosphatase activity. (1980) (14)
- Acute and long term effects on limb function of combined modality therapy in patients treated with limb sparing surgery for soft tissue sarcoma of the extremity (1990) (14)
- The effect of peripheral lymphoid cells on the incidence of lethal graft versus host disease following allogeneic mouse bone marrow transplantation. (1983) (13)
- New Approaches to the Adoptive Immunotherapy of Established Metastatic Cancer using Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 (1986) (13)
- The immunologic treatment of cancer (1988) (13)
- Assessment of Ovarian Function After Preparative Chemotherapy and Total Body Radiation for Adoptive Cell Therapy (2011) (13)
- The human mixed lymphocyte-tumor cell interaction test (1984) (13)
- A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. (2012) (13)
- Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer. (1991) (13)
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors (2022) (13)
- Systemic administration of recombinant interleukin-2 in mice (1984) (13)
- Lymphosarcoma: survival and the effects of therapy. (1961) (13)
- Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity (2006) (12)
- Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest (1994) (12)
- T cell receptor affinity and avidity defines antitumor response and autoimmunity in T cell immunotherapy (2013) (12)
- Combined modality therapy of cancer. What is it and when does it work? (1985) (12)
- Aphasia As a Complication Of CD19-Targeted Chimeric Antigen Receptor Immunotherapy (S52.006) (2014) (12)
- Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. (1994) (12)
- Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells (2017) (12)
- The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. (1994) (12)
- A simplified automated procedure for generation of human lymphokine-activated killer cells for use in clinical trials. (1988) (12)
- Orbital inflammatory disease associated with systemic lupus erythematosus. (1991) (12)
- Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies. (2014) (12)
- Long-Term Survival of Anti-Tumor Lymphocytes Generated by Vaccination of Patients With Melanoma With a Peptide Vaccine (2000) (12)
- Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor (2013) (11)
- The malignant melanoma of hamsters. II. Growth and morphology of a transplanted melanotic and amelanotic tumor in tissue culture. (1961) (11)
- Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells (2004) (11)
- Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. (2011) (11)
- The in vivo distribution of transferred syngeneic, allogeneic, and xenogeneic lymphoid cells: implication for the adoptive immunotherapy of tumors. (1980) (11)
- Regulation of Interleukin‐6 (IL‐6) by IL‐2 and TNF‐α in Human Peripheral Blood Mononuclear Cells (1989) (11)
- A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells (2010) (11)
- Isolation and characterization of lymphocytes infiltrating human renal cell cancer: Possible application for therapeutic adoptive immunotherapy (1986) (11)
- Effect of hydration on plasma-methotrexate levels. (1977) (11)
- CARs on Track in the Clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy Washington DC, 18 May 2010. (2011) (11)
- Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience. (2010) (11)
- Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes. (1983) (11)
- Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain (2020) (11)
- Suppression of interleukin-2 production by methylprednisolone (1983) (11)
- Measuring Tissue-Based Biomarkers by Immunochromatography Coupled with Reverse-Phase Lysate Microarray (2006) (11)
- Cancer : principles & practice of oncology : primer of the molecular biology of cancer/ editors, Vincent T. DeVita, Jr, Theodore S. Lawrence, Steven A. Rosenberg; with 82 contributing authors (2015) (10)
- In search of an effective antiemetic: a nusring staff participates in marijuana research. (1980) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Alkaline phosphatase measurements of paired normal and osteosarcoma tissue culture lines obtained from the same patient. (1979) (10)
- Adoptive immunotherapy of urologic tumors. (1989) (10)
- Surgical treatment of malignant melanoma. (1976) (10)
- Simplified techniques for the isolation of alloreactive cell lines and clones with specific cytotoxic or proliferative activity. (1983) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- CHAPTER 12 – INTERLEUKIN 2 AS A PHARMACOLOGIC REAGENT (1988) (10)
- Dramatic Regression of Chronic Lymphocytic Leukemia in the First Patient Treated With Donor-Derived Genetically-Engineered Anti-CD19-Chimeric-Antigen-Receptor-Expressing T Cells After Allogeneic Hematopoietic Stem Cell Transplantation (2011) (10)
- The management of isolated renal recurrence of renal cell carcinoma following complete response to interleukin-2 based immunotherapy. (1993) (10)
- Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee (2020) (10)
- A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers (2015) (10)
- Technical aspects of lymphokine‐activated killer cell production (1988) (10)
- The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis. (1991) (10)
- Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer. (2019) (10)
- National Cancer Institute Experience in the Management of High-Grade Extremity Soft Tissue Sarcomas (1988) (10)
- The significance of bone scan abnormalities in patients with primary osteogenic sarcoma (1984) (10)
- CCR 20th Anniversary Commentary: Autologous T Cells—The Ultimate Personalized Drug for the Immunotherapy of Human Cancer (2015) (10)
- Malignant melanoma: a search for occult lymph node metastases. (1981) (10)
- Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells (2006) (9)
- Human gene marker/therapy clinical protocols. (1997) (9)
- Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation (2013) (9)
- Reply to "Cancer vaccines: pessimism in check" (2004) (9)
- Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. (2021) (9)
- Quantitation of T-Cell Receptor Frequencies by Competitive Polymerase Chain Reaction: Dynamics of T-Cell Clonotype Frequencies in an Expanding Tumor-Infiltrating Lymphocyte Culture (2000) (9)
- Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial. (1976) (9)
- BLOCKING BY CYCLOSPORINE OF ANTIGEN‐INDUCED MATURATION AND LYMPHOKINE SECRETION BY CYTOTOXIC T LYMPHOCYTE HYBRIDOMAS (1984) (9)
- Identification of a T-cell receptor from a therapeutic murine T-cell clone. (1997) (9)
- Propagation of mouse and human T cells with defined antigen specificity and function. (1994) (9)
- The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas. (1985) (9)
- Study on Adoptive Immunotherapy Using Gene-Modified TCells for Ovarian Cancer (2006) (9)
- Isolation perfusion with tumor necrosis factor-alpha, interferon-gamma, and hyperthermia in the treatment of localized and metastatic cancer. (1995) (9)
- Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid (2005) (9)
- Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. (1989) (8)
- Neoantigen Identification and Response to Adoptive Cell Transfer in anti PD-1 Naïve and Experienced Patients with Metastatic Melanoma. (2022) (8)
- Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells (2020) (8)
- A tumor-elaborated supernatant factor chemotactic for IL-2 expanded tumor infiltrating T-lymphocytes. (1993) (8)
- Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR (2018) (8)
- Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy (2021) (8)
- Comparison of in vivo cell distribution following either intraperitoneal or intravenous injection of lymphoid cells. (1980) (8)
- Genetically engineered T-cell therapy for HPV-associated epithelial cancers: A first in human, phase I/II clinical trial. (2018) (8)
- Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities. (2003) (8)
- Phase I study of human leukocyte interferon in patients with advanced cancer. (1983) (8)
- Clinical trials with IL-2. (1986) (8)
- Proteins synthesized in lymphoid cells early after activation by phytohemagglutinin. (1973) (8)
- Decreased Tolerance to Interleukin-2 With Repeated Courses of Therapy in Patients With Metastatic Melanoma or Renal Cell Cancer (2000) (8)
- Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma (2012) (8)
- The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease. (1985) (8)
- T Cell‐Receptor V Gene Use by CD4+ Melanoma‐Reactive Clonal and Oligoclonal T‐Cell Lines (1998) (8)
- Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. (2006) (8)
- In vitro effect of methylprednisolone on protein synthesis of activated canine thymus-derived lymphocytes. (1975) (8)
- Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors. (2014) (8)
- Immersion in the search for effective cancer immunotherapies (2021) (7)
- Isolation of T cell receptors specifically reactive with mutated tumor associated antigens (2014) (7)
- regression and targets normal tissues expressing cognate antigen Gene therapy with human and mouse T-cell receptors mediates cancer (2009) (7)
- Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer. (1987) (7)
- Expression of oncofetal antigens by murine and human normal cells in tissue culture. (1978) (7)
- INTERLEUKIN-2 PRODUCES HEMODYNAMIC CHANGES SIMILAR TO SEPTIC SHOCK IN HUMANS (1986) (7)
- Immunohistologic Responses Within Dermal Metastatic Melanoma Lesions of Patients Treated With a Synthetic Peptide Vaccine (2000) (7)
- Early evaluation of mixed leukocyte interactions in mice and guinea pigs using measurements of protein synthesis. (1973) (7)
- Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires. (1989) (7)
- Response to Comment on “Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma” (2006) (7)
- Erratum: Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling (Journal of Clinical Investigation (2007) 117, (2197-2204) DOI:10.1172/JCI32205) (2007) (7)
- Normal adult murine cells in tissue culture express fetal antigens. (1977) (7)
- Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin. (1987) (7)
- PHASE I STUDIES OF THE PHARMACOKINETICS, TOXICITIES, AND BIOLOGIC EFFECTS OF INTERLEUKIN-6 IN PATIENTS WITH REFRACTORY ADVANCED MALIGNANCIES (1993) (6)
- Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting (2013) (6)
- A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute. (1999) (6)
- Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice (2005) (6)
- Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes. (1992) (6)
- Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes (2015) (6)
- Recurrent inactivating RASA 2 mutations in melanoma (6)
- Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. (2003) (6)
- Characterization of the murine lymphokine-activated killer precursor and effector cell (1985) (6)
- Future prospects for immunotherapy (1975) (6)
- Cellular therapy: an introduction. (2001) (6)
- Characterization of T-cell Receptors Directed Against HLA-A*01-restricted and C*07-restricted Epitopes of MAGE-A3 and MAGE-A12 (2012) (6)
- Comprar Colon And Other Gastrointestinal Cancers (From Cancer Principles And Practice Of Oncology, 10th Edition) | Vincent T. DeVita Jr. | 9781496333964 | Lippincott Williams & Wilkins (2016) (6)
- REGRESSION OF A DISSEMINATED SYNGENEIC SOLID TUMOR (2003) (6)
- Serologic analysis of human tumor antigens. II. Reactivity of sera from eleven osetogenic sarcoma patients against autologous and allogeneic tumor cells. (1979) (6)
- IL-2: The First Effective Immunotherapy for (2014) (6)
- DIFFERENT SPECIFICITIES OF CLONED T CELLS ASSESSED BY IN VITRO PROLIFERATION ASSAYS AND BY THE ABILITY TO MEDIATE SKIN GRAFT REJECTION IN VIVO (1987) (6)
- Pancreatic cancer (2000) (6)
- Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity (2021) (6)
- Cloning with antigens and interleukin 2 of murine T lymphocytes having distinct functions. (1987) (6)
- Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells. (2018) (6)
- Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment. (1985) (6)
- Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease (2015) (5)
- Enterocolitis in Patients After Antibody Blockade of CTLA-4. (2005) (5)
- Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells (1991) (5)
- Tumor-specific CD8+ T cells expressing IL-12 eradicate established cancers in lymphodepleted hosts (2010) (5)
- Gene therapy of cancer. (1994) (5)
- Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma (2021) (5)
- Soft tissue sarcoma in adults. Randomized Trials in Cancer: A Critical Review by Sites (1978) (5)
- IDENTIFICATION OF HUMAN CANCERS DEFECTIVE IN ANTIGEN PROCESSING (1993) (5)
- Steroid suppression of protein synthesis of activated human lymphocytes. (1976) (5)
- Adjuvant treatment of soft tissue sarcoma in children and adults. (1978) (5)
- The Kinetics of Interleukin‐6 Induction by the Systemic Administration of rhTNF‐α in Mice (1989) (4)
- Alternating chemotherapy and irradiation in advanced Hodgkin's disease (1984) (4)
- The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment. (1988) (4)
- Interferon y and Tumor Necrosis Factor Have a Role in Tumor Regressions Mediated by Murine CD8+ Tumor-infiltrating Lymphocytes (2003) (4)
- 8 – IN VITRO ASSAY FOR INHIBITION OF MIGRATION OF HUMAN BLOOD LEUCOCYTES (1971) (4)
- The Transformed Cell (1992) (4)
- Preliminary results of a prospective randomized trial of intraoperative (IORT) and low dose external beam radiotherapy vs high dose external beam radiotherapy as adjunctive therapy in resectable soft tissue sarcomas of the retroperitoneum (1986) (4)
- Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells. (1990) (4)
- Levels of cytotoxic reactivity to cultured normal skin fibroblasts in sera from normal and sarcoma-bearing patients. (1980) (4)
- Erratum: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (Cancer Immunol Immunother DOI 10.1007/s00262-011-0977-7) (2011) (4)
- Identification of Endogenous HLA-A2–Restricted Reactivity Against Shared Melanoma Antigens in Patients Using the Quantitative Real-Time Polymerase Chain Reaction (2002) (4)
- Abstract 2990: Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma (2017) (4)
- The Emergence of Modern Cancer Immunotherapy (2005) (4)
- 38 – Potential Use of Expanded T Lymphoid Cells and T Cell Clones for the Immunotherapy of Cancer (1982) (4)
- BRAF Inhibition: Bridge or Boost to T-cell Therapy? (2019) (4)
- Effects of interleukin 2 therapy on lymphocyte magnesium levels. (2002) (4)
- Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy (2015) (4)
- NIH conference. Immunomodulators in clinical medicine. (1987) (4)
- Cytotoxic antibody reactivity in sera of melanoma patients against allogeneic and autologous cultured tumor cells and fibroblasts. (1982) (4)
- Cancer Therapy : Preclinical Determinants of Successful CD 8 þ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice (2011) (4)
- Tumor-specific lysis by long-term cultured tumor-infiltrating lymphocytes (1987) (4)
- Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia. (2020) (4)
- Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide. (2000) (4)
- Successful therapy of hepatic metastases from several murine tumors using lymphokine-activated killer cells and recombinant interleukin-2 (1985) (4)
- Development of new immunologic approaches to cancer therapy. (1988) (3)
- 333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program (2020) (3)
- A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma. (1985) (3)
- Adoptive transfer of tumor infiltrating lymphocytes for metastatic cervical cancer (2013) (3)
- Local Delivery of lnterleukin-12 using T cells Targeting Vascular Endothelial Growth Factor Receptor-2 Eradicates Multiple Vascularized Tumors in Mice (2012) (3)
- Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes (2015) (3)
- Hodgkin's disease: no stage beyond cure. (1986) (3)
- A Phase-II Study of Ifosfamide in the Treatment of Recurrent Sarcomas and Pediatric Tumors (1987) (3)
- Curative Non-surgical Combined Treatment of Squamous Cell Carcinoma of the Oesophagus (1992) (3)
- The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease. (1992) (3)
- Advances in Brief Generation of NY-ESO-1-specific CD 4 and CD 8 T Cells by a Single Peptide with Dual MHC Class I and Class II Specificities : A New Strategy for Vaccine Design (2002) (3)
- CHARACTERIZATION OF HUMAN TUMOR CELL LINES TRANSDUCED WITH cDNA CODING EITHER TUMOR NECROSIS FACTOR (TNF) OR INTERLEUKIN-2 (IL-2) (1992) (3)
- Cellular Characterization and Retroviral Transduction of Short‐Term Breast Cancer Cells (1995) (3)
- New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer (2012) (3)
- Lack of antihypertensive effect of interleukin-2 administration in humans. (1991) (3)
- Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy. (1980) (3)
- Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2019) (3)
- Immune depression associated with BCG septicemia: longitudinal evaluation of melanoma patients using simultaneous assay of cryopreserved lymphocytes (1977) (3)
- Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities (2019) (3)
- GENE-MODIFICATION CORRECTS AN ANTIGEN PRESENTATION DEFECT IN A NON-IMMUNOGENIC SARCOMA AND ELICITS CD8+ T CELLS REACTIVE AGAINST THE WILD-TYPE TUMOR: IMPLICATIONS FOR THE IMMUNOTHERAPY OF CANCER (1992) (3)
- Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia (2014) (3)
- 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015). (2015) (3)
- The Use of Lymphoid Cells Expanded in IL-2 for the Adoptive Immunotherapy of Murine and Human Tumors (1984) (3)
- A sensitive assay for the detection cytotoxic antibodies to mammalian cell surface antigens. (1979) (3)
- Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma (2014) (3)
- Effects of protein-calorie restriction on the immune response to skin allografts in the rat. (1980) (3)
- Chapter 11. Anti-angiogenesis as a therapeutic strategy for cancer (2000) (3)
- T Cell Immunotherapy: Optimizing Trial Design (2014) (3)
- SEVEN Adoptive T-Cell Therapy for Cancer (2016) (3)
- Delta-9-Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High-Dose Methotrexate (2020) (3)
- In Vitro Growth of Cytotoxic Human Lymphocytes (1978) (3)
- B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor (2011) (3)
- Successful systemic adoptive immunotherapy of a disseminated solid syngeneic murine tumor with long-term cultured t cells. (1983) (3)
- T-cell subpopulations mediating rejection of solid syngeneic tumors after systemic adoptive immunotherapy. Abstr. (1983) (2)
- Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL Running Head: Polyfunctional CAR T cell-associated clinical outcomes (2018) (2)
- Treatment of soft tissue and bone sarcomas: review of studies at the National Cancer Institute. (1981) (2)
- Human tumor antigens recognized by T lymphocytes : 296 (2005) (2)
- Ophthalmologic evaluation in patients undergoing immunization with melanoma-associated antigens. (1999) (2)
- Tumor lysis by human T lymphocytes in long-term culture and their distribution in vivo; implications for immunotherapy (1980) (2)
- Reconstitution of peripheral CD4+FOXP3+ regulatory T cells in cancer patients receiving adoptive immunotherapy is related to the clinical response to therapy. (131.18) (2010) (2)
- Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4 (cid:49) T Cells (1999) (2)
- Antigen/mitogen induced cytolytic activity and IL-2 secretion in memory-like CTL-hybridomas. (1985) (2)
- Heterogeneous lymphokine-activated killer cell precursor populations (2004) (2)
- Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients. (2012) (2)
- ASSESSMENT OF MIXED LYMPHOCYTE REACTIVITY IN HUMAN BONE MARROW CELL CULTURES (1985) (2)
- In vivo use of cytokines (1984) (2)
- Tetramer based approach for efficient identification and isolation of neo-antigen specific CD8 T cells from peripheral blood (PBL) of patients with metastatic cancers (2015) (2)
- Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma (2003) (2)
- Combined treatment approaches to soft tissue sarcomas. (1987) (2)
- Immunotherapy with lymphokine combinations. (1989) (2)
- Surgery and Adjuvant Radiation- Chemo-Immunotherapy in Soft Tissue Sarcomas: Result of Treatment at the National Cancer Institute (1980) (2)
- Surgery and Adjuvant Chemo-Immunotherapy in Osteosarcoma: Review of Treatment at The National Cancer Institute (1980) (2)
- A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Nystatin on the Development of Oral Irritation in Patients Receiving High-Dose Intravenous Interleukin-2 (2001) (2)
- 152 Adoptive T cell therapy targeting somatic p53 mutations (2020) (2)
- Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). (2012) (2)
- Chemical Aspects and Biosynthesis (1972) (2)
- A randomized trial comparing mastectomy versus excisional biopsy plus radiation in the treatment of stage I and II breast cancer (1984) (2)
- Antilymphocyte globulin as the sole immunosuppressant for bone marrow transplantation in aplastic anemia. A case report. (1973) (2)
- Growth and antitumor activity of tumor-involved draining lymph node cells versus tumor-infiltrating lymphocytes from patients with renal cell cancer (1987) (2)
- Abstract 4982: Regression of metastatic breast cancer after adoptive cell transfer of tumor infiltrating lymphocytes and checkpoint blockade (2017) (2)
- NCI Primary Malignant Melanoma Study (1976) (2)
- Adjuvant chemotherapy of adult patients with soft tissue sarcomas. (1985) (2)
- Pathophysiologic Effects of Interleukin-2 on Renal Function in 135 Patients Receiving Immunotherapy for Advanced Cancer (1987) (2)
- Comprar Prostate And Other Genitourinary Cancers (From Cancer Principles And Practice Of Oncology, 10th Edition) | Vincent T. DeVita Jr. | 9781496333971 | Lippincott Williams & Wilkins (2016) (2)
- NMDA Receptor-PSD-95 Protein Interactions Treatment of Ischemic Brain Damage by Perturbing (2006) (2)
- Diversity of mutated antigen recognition by tumor infiltrating lymphocytes from patients with metastatic melanoma (2015) (2)
- 391. Mutated Tumor Neoantigens Are Recognized by Tumor Infiltrating Lymphocytes from Metastatic Ovarian Cancer (2016) (2)
- Demonstration of shared recognition and lysis of autologous and allogeneic fresh human tumors by cloned lymphokine-activated killer cells (1984) (1)
- Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. (1987) (1)
- 190 Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers (2021) (1)
- IL-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH KIDNEY IN PLACE (1999) (1)
- Interleukin 2 Therapy for Disseminated Cancer-Reply (1987) (1)
- Adoptively transferred tumor-infiltrating T cells target somatic cancer mutations in a human papillomavirus+ cancer patient with complete tumor regression (2015) (1)
- Abstract IA14: Cell transfer immunotherapy targeting unique somatic mutations in cancer (2019) (1)
- The Treatment of Soft‐tissue Sarcomas of the Extremities: Prospective Randomized Evaluations of (1) Limb-sparing surgery Plus Radiation Therapy Compared with Compared with amputation and (2) the Role of adjuvant Chemotherapy (1982) (1)
- Vaccination trials and response monitoring using the defined melanoma-associated antigen Mart-1 and Gp-100: 083 (1997) (1)
- for adoptive immunotherapy T cells + IL-2 and IL-21 confer opposing differentiation programs to CD8 (2010) (1)
- A Journey in Science: Immersion in the search for effective cancer immunotherapies (2021) (1)
- Serologic analysis of human tumor antigens (1981) (1)
- Antigens Recognizes MAGE-12 Expression of Melanoma Differentiation Melanoma Metastasis with Decreased A Tumor-Infiltrating Lymphocyte from a Rosenberg and (2000) (1)
- Immunotherapy and Gene Therapy of Cancer1 (1992) (1)
- 651 Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction (2021) (1)
- Abstract IA19: Curative potential of T-cell immunotherapy for cancer (2015) (1)
- New Approaches to the Immunotherapy of Cancer Based on the Systemic Administration of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 (1986) (1)
- Role of the spleen in the transdiaphragmatic spread of Hodgkin's disease. (1987) (1)
- Evaluation in mice of the capillary leak syndrome (CLS) mediated by the systemic administration of recombinant interleukin-2 (IL-2) (1986) (1)
- Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR. (2014) (1)
- Stimulation by recombinant interleukin-2 (IL-2) of in vivo proliferation of endogenous lymphoid cells and transferred lymphokine activated killer (LAK) cells in mice (1985) (1)
- The impact of the cancer genome project and high-throughput analyses on personalised oncology: today and tomorrow (2012) (1)
- MetabolicImagingof Human Extremity MusculoskeletalTumors by PET (1988) (1)
- Melanoma-associated B cells are distinct from peripheral blood-derived B cells, and may serve as a source of tumor-targeting antibodies (2013) (1)
- Biomarker analysis of patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells. (2015) (1)
- Vascular leak syndrome associated with the administration of lymphokine-activated killer cells and interleukin-2 to mice (1986) (1)
- Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma (1988) (1)
- Clinical Trials of Immunotherapy of Cancer Utilizing Cytotoxic Cells (1993) (1)
- High frequency CD8+PD-1+ TCR clonotypes isolated from fresh melanomas display anti-tumor activity (2015) (1)
- Abstract 127: Single cell mapping of tumor infiltrating lymphocytes enables neoantigen-reactive T cell identification in metastatic human cancer (2021) (1)
- alloproteinase as a Novel Driver in Melanoma (2010) (1)
- Abstract OT1-01-03: Adoptive cell transfer (ACT) using tumor infiltrating lymphocytes to target neoantigens in patients with metastatic breast cancer (2016) (1)
- Abstract 2305: Comparative evaluation of peripheral blood T cells and resultant engineered anti-CD19 CAR T cell products from relapsed/refractory non-Hodgkin's lymphoma (NHL) patients (2016) (1)
- Tumor cell susceptibility to lysis: Marked increase in lysis by tumor-infiltrating lymphocytes following target stimulation with interferon-γ and tumor necrosis factor-α - Implications for immunotherapy (1987) (1)
- Specific increase in T-cell potency via structure-based design of a T-cell receptor for adoptive immunotherapy. (2014) (1)
- Immunotherapy of lung micrometastases from a murine sarcoma with recombinant interleukin-2: Mechanism of action (1985) (1)
- Abstract P2-04-02: Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases (2017) (1)
- Successful adoptive immunotherapy of a disseminated murine cancer using immunized cells expanded in T-cell growth factor (1981) (1)
- Abstract LB-138: Autologous-collected anti-cd19 chimeric antigen receptor (CAR) T cells for acute lymphocytic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL) in children who have previously undergone allogeneic hematopoietic stem cell transplantation (HSCT). (2013) (1)
- Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience (2022) (1)
- The use of cryopreserved lymphocytes stored for more than 6 months in assays of cellular immunity of normal volunteers and patients with cancer (1976) (1)
- Autologous-collected anti-CD19 chimeric antigen receptor T cells (19CARTs) for pediatric acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL): Clinical activity and cytokine release without graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). (2013) (1)
- Secrecy in research: cooperation and costimulation in immunology. (1996) (1)
- 979. Clonal Expansion of a CD8+ T Cell Clone after Retroviral Transduction of Mature T Lymphocytes with the IL-15 Gene (2006) (1)
- Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma (2012) (1)
- 185. Cloning and Modification of a T-Cell Receptor Gene Targeting Tyrosinase Confers Peptide and HLA Specific Reactivity to Transduced Peripheral Blood Lymphocytes (2009) (1)
- Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. (2006) (1)
- Tumor-specific lysis by tumor-infiltrating lymphocytes derived from melanomas (1988) (1)
- The changing approach to cancer surgery. (1985) (1)
- A rapid single-cell RNA-seq approach to identify neoantigen-specific T-cell receptors targeting tumor-specific mutations for use in gene-engineered T-cell immunotherapy (2017) (1)
- Abstract 3114: Mutational inactivation of STAG2 causes aneuploidy in human cancer (2012) (1)
- Advances in Brief The Waardenburg Syndrome Type 4 Gene , SOX 10 , Is a Novel Tumor-associated Antigen Identified in a Patient with a Dramatic Response to Immunotherapy (2002) (0)
- Treatment of recurrent sarcomas and pediatric solid tumors with ifosfamide (IF) (1986) (0)
- Abstract 4970: Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma (2011) (0)
- Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma (2020) (0)
- Cancer Immunotherapy 14 HUMAN TUMOR ANTIGENS (2014) (0)
- Anran Wang Cells That Can Self-Renew After Adoptive Transfer in Humans mRNA Defines Memory T γ The Stoichiometric Production of IL-2 and IFN (2012) (0)
- 767. Genetic Engineering of an Immortal Human CD8+ T Cell Line (2006) (0)
- Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells (2019) (0)
- Adoptive transfer of autologous tumor-infiltrating lymphocytes in metastatic human papilloma virus-induced carcinoma (VAC7P.1040) (2015) (0)
- Activated lymphocytes with dual specificity and their use methods (2002) (0)
- Functional Heterogeneity of Vaccine-Induced (2013) (0)
- in Vivo α Lungs of Mice by Administration of Recombinant Interleukin 1 Decrease in Interleukin 2-induced Vascular Leakage in the (2013) (0)
- Abstract IA01: T cells as a drug for the personalized immunotherapy of cancer (2016) (0)
- UK route of administration of recombinant vaccinia vitas (rVV) vaccines effects the active treatment of cancer (1996) (0)
- Antitumor Activity Human Renal Cell Cancer : Isolation , Characterization , and Interleukin 2 Expanded Tumor-infiltrating Lymphocytes in Updated Version (2006) (0)
- Abstract KN03: Keynote Lecture: Cell transfer immunotherapy targeting unique somatic mutations in cancer (2018) (0)
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma (2020) (0)
- Substitution of alpha aminobutyric acid for cysteine at class I MHC anchor positions can enhance recognition of cancer epitopes (2019) (0)
- Adoptive immunotherapy with T cells enhanced survival. (2005) (0)
- Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis (2017) (0)
- Chimeric T cell receptors, and related materials and methods for using (2007) (0)
- 162 Small molecule inhibition of the Bcl-2 family (2006) (0)
- Erratum: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes (Journal of Experimental Medicine (February 1995) 181 (799-804)) (1995) (0)
- The Buzaid article reviewed (2004) (0)
- Hematopoietic Stem Cell Transplant With Lymphodepletion Augments T Cell-based Adoptive Immunotherapy (2005) (0)
- VivoPartial Reduction in Regulatory T Cells In Metastatic Melanoma Induces a Selective Immunotoxin, LMB-2, to Patients with Administration of a CD25-Directed (2007) (0)
- Unique neoantigens expressed by melanomas and common epithelial cancers presented by multiple HLA alleles can be efficiently identified utilizing peptide prediction algorithms (2015) (0)
- 410: Bone Mineral Density in Prostate Cancer Patients Undergoing Initial Androgen Deprivation Therapy: Zoledronic Acid VS. Placebo (2006) (0)
- Human Cancer IL-2 : The First Effective Immunotherapy (2014) (0)
- Antitumor Efficacy Demonstrate Superior In Vitro and In Vivo High Avidity CTLs for Two Self-Antigens (1998) (0)
- CTLA-4 Blockade'' and Autoimmunity in Patients Treated with Cellular Mechanism of Antitumor Responses Response to Comment on ''Analysis of the (2006) (0)
- RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2018) (0)
- Personalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens (2015) (0)
- Transduction and differentiation of dendritic cells from human hematopoietic progenitor cells (1996) (0)
- Gene therapy for melanoma holds promise (1991) (0)
- Human gene marker/therapy clinical protocols. (1996) (0)
- Cell Lines Recognize and Kill Diverse Human Tumor with NY-ESO-1 Antigen-Specific TCR Genes Primary Human Lymphocytes Transduced (2005) (0)
- Abstract 2221: Analysis of the protein tryosine kinome in melanoma revealed recurrent mutations inERBB4 (2010) (0)
- IN VITRO PREDICTORS OF CLINICAL RESPONSE IN MELANOMA PATIENTS RECEIVING TUMOR INFILTRATING LYMPHOCYTE (TIL) IMMUNOTHERAPY (1993) (0)
- Factors A ssociated W ith R esponse t o H igh-Dose Interleukin-2 i n P atients W ith M etastatic M elanoma (2001) (0)
- 167 High-efficiency capture of anti-tumor neoantigen-reactive T cell receptors from tumor digest (2021) (0)
- Treatment of metastatic uveal melanoma with adoptive transfer of tumor infiltrating lymphocytes: a single-center phase 2 study (2017) (0)
- Ef fi cacy of abbreviated Stanford V chemotherapy and involved-fi eld radiotherapy in early-stage Hodgkin lymphoma : mature results of the G 4 trial † (2013) (0)
- Vitro to Alloantigens Lymphocytes : I . Growth of Cells Sensitized in Growth of Cytotoxic Human In Vitro (2006) (0)
- Activation of naïve CD8+ T cells by memory cells impairs antitumor immunity in adoptive cell transfer (2011) (0)
- Adoptive cell therapy targeting common p53 neoantigens in human solid cancers (2021) (0)
- 200 Years after Jenner: The Search for a Cancer Vaccine (2000) (0)
- IL-7 and IL-15 can trigger cancer regression after adoptive transfer of CD8+T lymphocytes (2004) (0)
- Increased reliability of cellular immune assays with cryopreserved lymphocytes: studies in humans. (1976) (0)
- Abstract 3966: Development of a fully-human chimeric antigen receptor against PSCA for the treatment of pancreatic cancer. (2013) (0)
- immunization with a recombinant adenovirus Therapeutic antitumor response after (2001) (0)
- Abstract CT003: A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer (2016) (0)
- Serologic analysis of human and mouse tumor antigens using a post-labeling microcytotoxicity assay (1979) (0)
- Hodgkins disease pathologic stage i ii the prognostic importance of initial sites of disease and extent of mediastinal involvement (1980) (0)
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (2018) (0)
- Cellular and molecular characterization of a helper/inducer T-cell clone with lytic specificity isolated from renal cell carcinoma ascitic fluid (1988) (0)
- Anti-Melanoma Peptide Vaccination Systemic Immune Response During Functional Dissociation Between Local and (2013) (0)
- Cytokine Therapy of Patients with Cancer (1989) (0)
- NY-ESO-1 Differentiates Synovial Sarcoma From Other Sarcomas (2012) (0)
- Cellular mechanisms of anti-tumor responses in patients treated with CTLA-4 blockade (2005) (0)
- Abstract A175: Memory T-cells targeting unique and shared oncogenic mutations detected in peripheral blood of epithelial cancer patients (2019) (0)
- and remain responsive to antigen Interleukin-2-transduced lymphocytes grow in an autocrine fashion (2011) (0)
- Expression of inhibitors of urokinase (1994) (0)
- a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the (1999) (0)
- A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Nystatin on the Development of Oral Irritation in Patients Receiving High-Dose Intravenous Interleukin-2. (2001) (0)
- Abstract B055: Enhanced detection of T-cells targeting unique neoantigens and shared mutated oncogenes for personalized cancer immunotherapy (2019) (0)
- Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers (2014) (0)
- Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor (2012) (0)
- Specific adoptive immunotherapy: Characterization of lymphoid subpopulations involved in tumor rejection (1986) (0)
- Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients (2019) (0)
- OR.86. Accumulation of Tumor Infiltrating FOXP3+ CD4+ Regulatory T Cells in Tumors and Not in Peripheral Blood in Patients with Melanoma (2008) (0)
- Abstract 1509: A signature for tumor neoantigen-reactive T-cells in fresh human lung cancers allows rapid cloning of their receptors (2021) (0)
- 272. Rapid Identification of Tumor- and Neoantigen-Reactive T-Cell Receptors for Personalized Immunotherapy (2016) (0)
- High-Dose R ecombinant I nterleukin 2 T herapy f or P atients With M etastatic M elanoma: A nalysis o f 2 70 P atients Treated B etween 1 985 a nd 1 993 (1999) (0)
- Engineering the immune response to "self" for effective cancer immunotherapy (2014) (0)
- Abstract 4860: Exon capture analysis of G-protein coupled receptors reveals activating mutations inGRM3in melanoma (2012) (0)
- New approaches to the immunotherapy of cancer (1988) (0)
- Towards Deciphering the Genetic Landscape in Melanoma (2012) (0)
- Regression Following Immunotherapy From a Patient With a Durable Complete MHC Class II Region Using Lymphocytes Reading Frame of a Gene in the Extended Translated From an Alternative Open Identification of BING-4 Cancer Antigen (2002) (0)
- Abstract 2762: Single-cell analysis of circulating neoantigen-reactive CD8+ T cells allows isolation of novel tumor reactive TCRs (2022) (0)
- , The signal sequence peptide of the endoplasmic reticulum, and peptide-encode at least one other, their use in vaccines and to treat diseases (1994) (0)
- Needle Aspirates of Melanoma Metastases Expansion of Tumor-T Cell Pairs from Fine Marincola (1999) (0)
- Molecular Cancer esearch cer Genes and Genomics ational and Functional Analysis Reveals ADAMTS 18 R alloproteinase as a Novel Driver in Melanoma (2010) (0)
- Cell transfer and other immunotherapeutic strategies. (2005) (0)
- Adoptive transfer of T-lymphocyte clones can mediate skin graft rejection (1983) (0)
- Study of tumor-infiltrating T-cell reactivity to metastatic gastrointestinal cancers. (2012) (0)
- Abstract LB-065: Mutational and functional analysis of the tumor suppressor PTPRD in human melanoma (2015) (0)
- Combination lymphokine therapy: Synergistic antitumor effects of tumor necrosis factor, interleukin-2, and interferon-alpha against established murine subdermal and hepatic tumors (1988) (0)
- Su.65. PD-1 is Expressed by Human Tumor Infiltrating T Cells in Tumors but not in Peripheral Blood and its Expression Correlates with Impaired Effector Function (2008) (0)
- Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma (2020) (0)
- Abstract LB-221: Diversity of tumor infiltrating lymphocyte recognition of diverse mutated antigens in cutaneous melanoma (2015) (0)
- Abstract LB-48: Somatic mutation of the NMDAR subunit GRIN2A in malignant melanoma results in loss of tumor suppressor activity. (2013) (0)
- The Isolation and Expansion of Lymphocytes Infiltrating Human Renal Tumors Using Recombinant Interleukin-2; Possible Application for Clinical Use (1987) (0)
- Phase I clinical trial of infusion into cancer patients of autologous lymphocytes activated in vitro with lectins (1982) (0)
- Lymphodepletion Patients with Metastatic Melanoma following Peripheral Blood Mononuclear Cells to Adoptive Transfer of Vaccine-Induced (2006) (0)
- Identification of a Shared / / LAA * 0207-restricted T-Cell Epitope from the Melanoma Antigen Tyrosinase-related Protein 2 ( TRP 2 ) 1 (2006) (0)
- Routine imaging to detect recurrences in high-risk melanoma patients. (2011) (0)
- Adjuvant Chemotherapy of Adult Soft Tissue Sarcomas (1983) (0)
- Abstract IA15: T-Cells targeting mutated RAS—clinical trials (2020) (0)
- Generation of rapidly proliferating tumor-infiltrating lymphocytes with cytolytic specificity and therapeutic efficacy in mice (1989) (0)
- Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer (2015) (0)
- [351] Clinical studies in cancer surgery/cancer rehabilitation (1991) (0)
- MART-1/MelanA and gp100/PMel17 immunodominance revisited: Direct enumeration of frequency of melanoma differentiation antigen (MDA)-specific T-cells in tumor metastases TIL cultures (2001) (0)
- IFN-gamma production by adoptively transferred CD8+ T lymphocytes and host cells contributes to successful tumor immunotherapy (2004) (0)
- Approaches to cancer immunotherapy based on breaking tolerance to non-mutated antigens overexpressed on metastatic cancers (2003) (0)
- The organization of surgical oncology in university departments of surgery. (1984) (0)
- Clinical trials referral resource. Clinical trials at the surgery branch of the NCI. (1995) (0)
- Individual cultures of melanoma tumor infiltrating lymphocytes possess distinct patterns of reactivity with mutated antigens identified by whole exome sequencing of autologous tumors (2014) (0)
- current status and future prospects (1988) (0)
- Targeting Tyrosinase Engineered with a Highly Avid TCR Effective In Vivo Tumor Treatment When Both CD4 and CD8 T Cells Mediate Equally (2010) (0)
- Toll-like Receptors inTumor Immunotherapy (2007) (0)
- Protocol design for lymphokine testing in clinical studies of human cancer. (1986) (0)
- Gold compounds inhibit mitogen-induced immunoglobulin production in humans (1979) (0)
- Clinical Cancer esearch cer Therapy : Clinical cessful Treatment of Melanoma Brain R astases with Adoptive Cell Therapy (2010) (0)
- Abstract 3576: Identification of T-cell receptors targeting RAS hotspot mutations using TIL IVS in human cancers for use in cell-based immunotherapy (2022) (0)
- Randomized S tudy o f H igh-Dose a nd L ow-Dose I nterleukin-2 in P atients W ith M etastatic R enal C ancer (2003) (0)
- Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2019) (0)
- regression of large tumors across major histocompatibility barriers Adoptive transfer of allogeneic tumor-specific T cells mediates effective (2011) (0)
- Effect of Anti-Bl 6 Melanoma Monoclonal Antibody on Established Murine B 16 Melanoma Liver MÃ (2006) (0)
- Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens (2015) (0)
- e-Blood Circulating IL-15 exists as heterodimeric complex with soluble IL-15 R in human and mouse serum (2012) (0)
- Melanoma ' ' T Cells in Patients + Antigen-Specific CD 8 of Very High Levels of Self / Tumor Progression Can Occur despite the Induction Response to Comment on ' ' Tumor (2006) (0)
- Erratum: CD4+ t lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion (Cancer Immunology Immunotherapy (1995) 40 (1-9)) (1995) (0)
- A PROSPECTIVE RANDOMIZED TRIAL EVALUATING CRYSTALLOID VERSUS COLLOID FLUID RESUSCITATION FOR INTERLEUKIN-2 BASED THERAPY (1992) (0)
- Natural antibodies in human immune surveillance. (1972) (0)
- Book Review Principles and Practice of Research: Strategies for surgical investigators Second edition. Edited by H. Troidl and six others. 566 pp., illustrated. New York, Springer-Verlag, 1991. $99. (1991) (0)
- Lymphocytes and Antitumor Activity Leads to Enhanced Survival of Transduced T Receptor with Modified Signaling Domains A Herceptin-Based Chimeric Antigen (2009) (0)
- 912 Preferential recognition of neoantigens over non-canonical peptides in cancer patients (2021) (0)
- Specific increase in T cell potency via structure-based design of a T cell receptor for adoptive immunotherapy (2014) (0)
- Identification of a Shared //LA-A*0207-restricted T-Cell Epitope from the Melanoma Antigen Tyrosinase-related Protein 2 (TRP2)1 (2006) (0)
- F.151. Peripheral Blood Genes Differentially Expressed in Acute Cardiac Rejection Reflect Multiple Rejection Associated Pathways (2006) (0)
- Gene therapy for cancer. (1992) (0)
- Expansion of melanoma-reactive T cells from peptide- stimulated PBL of vaccinated patients is oligoclonal in short term cultures (1998) (0)
- Expression in Response to Vaccination Short-Term Kinetics of Tumor Antigen (2001) (0)
- Antigensof Autologous Melanoma Glycoprotein 100 and Does Not Alter the Recognition of Melanoma Tumor Antigen Primary Human Lymphocytes Affords Avid High Efficiency TCR Gene Transfer into (2013) (0)
- Correction for Sim et al., High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D (2020) (0)
- Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma (2023) (0)
- 77. Clinical Scale Zinc Finger Nuclease (ZFN)-Driven Gene-Editing of PD-1 in Tumor Infiltrating Lymphocytes (TIL) for the Potential Treatment of Metastatic Melanoma (2015) (0)
- The use of t-cell growth factor (tcgf) to isolate and continuously grow t-cells infiltrating syngeneic murine solid tumors. Abstr. (1980) (0)
- Cancer journal: From the editors (2001) (0)
- In Vitro Growth of Murine T Cells (1978) (0)
- Levels of Cytotoxic Reactivityto Cultured NormalSkin Fibroblasts in Sera from Normal and Sarcoma-bearingPatients (2006) (0)
- Erratum: Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model (Journal of Immunotherapy (1999) 22 (489-496)) (2000) (0)
- MHC class I antigen restriction of tumor recognition by lymphocytes infiltrating human melanomas (1990) (0)
- Genetic inference of immune responsiveness of melanoma cancer patients to TIL therapy (2013) (0)
- A New Beginning for the Journal of Immunotherapy (2000) (0)
- Process for improving the serum half-life of biologically active molecules (1999) (0)
- Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma (2002) (0)
- Immunotherapy selected antigen specific lymphocytes in vitro after lymphocyte suppressive chemotherapy nonmyeloablative (2003) (0)
- In vitro expansion of lymphokine-activated killer cells leads to increased numbers of cells which can mediate the reduction of murine hepatic and pulmonary metastases when adoptively transferred with recombinant interleukin-2 (1986) (0)
- Peptide inhibitors of urokinase-activity (1994) (0)
- Effect of Anti-Bl 6 Melanoma Monoclonal Antibody on Established Murine B16 Melanoma Liver Métastases (2006) (0)
- Transient retroviral transfection for single patient cancer immunotherapy (2015) (0)
- Lymphoid subpopulations in radiation induced allogeneic mouse chimeras. Abstr. (1979) (0)
- IRF5 gene polymorphisms in melanoma (2012) (0)
- Melanoma patients with durable responses to IL-2 treatment: role of surgical salvage for persistent or recurrent disease (1997) (0)
- enrichment, stimulation, and viral transduction of naive and central memory CD8 + T cells under GMP conditions for translational research towards the development of adoptive cell therapy of cancer patients (2013) (0)
- T Lymphocytes Recognized by Autologous Tumor-Infiltrating MART-2 , Containing a Mutated Epitope Isolation of a New Melanoma Antigen (2001) (0)
- Advances in Brief Expression of a “ Self-” Antigen by Human Tumor Cells Enhances Tumor Antigen-specific CD 4 T-Cell Function (2002) (0)
- Structure-Based Design of a TCR Specific Increase in Potency via (2014) (0)
- Adoptive immunotherapy with enhanced T-lymfocytoverlevelse (2005) (0)
- with a Dramatic Response to Immunotherapy the NY-ESO-1 Melanoma Antigen in a Patient Protein (TRP)-2, a New TRP-2 Isoform, and Pre-Existing Immunity to Tyrosinase-Related (2001) (0)
- HLA-A 1 ,-A 2 , andA 3 Alleles Infiltrating T Lymphocytes Restricted by Melanosomal Proteins Recognized by Tumor Identification of New Melanoma Epitopes on Sakaguchi (1998) (0)
- Adriamycin cardiotoxicity — Assessment of late left ventricular dysfunction by radionuclide cineangiography (1980) (0)
- 184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers (2021) (0)
- Patient with Melanoma Tumor-Infiltrating Lymphocytes from a Differentiation Antigens Are Recognized by Multiple HLA Class II-Restricted Melanocyte (2002) (0)
- 773 Adoptive Cell Therapy Response in Melanoma is Mediated by Stem-like CD8 T cells (2020) (0)
- Prolonged growth of rat and murine T-cells for possible use in adoptive immunotherapy (1979) (0)
- Epitope-Specific Immunization Kinetics of TCR Use in Response to Repeated (2013) (0)
- Abstract PR002: Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens (2016) (0)
- Crompton, Sukumar et al on Akt Cancer Res Jan 15 2015 (2015) (0)
- Memory T cells in the tumor-infiltrating lymphocytes for adoptive cell transfer therapy (B145) (2007) (0)
- Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase. (2001) (0)
- Human cancer immunotherapy: progress and problems (2006) (0)
- Abstract 1068: Tumor infiltrating lymphocytes (TIL) recognize a unique and diverse number of non-synonymous somatic mutations in patients with metastatic breast cancer (2020) (0)
- for Combination Metastatic Colorectal Cancer Using 5Fluorouracil, Leucovorin and Interleukin-2 (1993) (0)
- CAN-10-0735 Cancer esearch oenvironment and Immunology or-Specific CD 8 + T Cells Expressing Interleukin-12 R dicate Established Cancers in Lymphodepleted Hosts (2010) (0)
- Identification of mutation-specific tumor infiltrating lymphocytes from metastatic ovarian cancer (2015) (0)
- IL-2 ACTIVATED KILLER CELLS DISTINCT FROM NK AND T CELLS the top with a Pasteur pipette , and washed in CM (2003) (0)
- Optimizing conditions for the cryopreservation and recovery of human lymphoid cells for in vitro immune assays (1975) (0)
- Impact o f t he N umber o f T reatment C ourses o n t he Clinical R esponse o f P atients W ho R eceive H igh-Dose Bolus I nterleukin-2 (2008) (0)
- Abstract IA24: T cells as a drug for the personalized immunotherapy of cancer (2020) (0)
- Exogenous Cytokine Persist Long-Term in the Absence of Cytokine Withdrawal-Induced Apoptosis and with a Codon-Optimized IL-15 Gene Resist Primary Human T Lymphocytes Engineered (2005) (0)
- Functional heterogeneity of vaccine-induced CD8+ T cell subset (2002) (0)
- Human cancer antibody ny eso-1 / cag-3 and genean coding therefor (1998) (0)
- Human gene marker/therapy clinical protocols. (1999) (0)
- Salvage therapy and prognostic factors for patients (PTS) relapsing following radiotherapy for stage I, II, and IIIA/B Hodgkin's disease (HD) (1986) (0)
- Antigen , OA 1 Vivo to a Novel Self / Tumor Melanoma Tissue Enhances Human T Cell Responses In Normal Tissue Depresses While Tumor (2003) (0)
- astases with Adoptive Cell Therapy (2010) (0)
- DeVita, Hellman, and Rosenberg's cancer vol.1 (2012) (0)
- Enhancement of cell mediated cytotoxicity following immunization with neuraminidase treated cells (1974) (0)
- 454. Recognition of Tumor Antigens by In Vitro Developed T Cells from Hematopoietic Stem Cells Retrovirally Transduced with TCR Genes (2006) (0)
- Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred (2004) (0)
- Lymphocytes a double specificite actives et procedes d'utilisation de ceux-ci (2002) (0)
- Lymphoplasmapheresis in rheumatoid arthritis. (1982) (0)
- In vivo administration of lymphokines: A new approach to immune regulation (1983) (0)
- Distinct Histological Types Immunogenic and Nonimmunogenic Murine Tumors of Three of Established Pulmonary Metastases from Weakly Recombinant Interleukin 2 in Vivo: Successful Immunotherapy Antitumor Efficacy of Lymphokine-activated Killer Cells and (2013) (0)
- Adoptive cell transfer immunotherapy for patients with solid epithelial cancers. (2023) (0)
- Correction to: A Journey in Science: Immersion in the search for effective cancer immunotherapies (2021) (0)
- Lymphocytes Mononuclear Cells and Tumor-Infiltrating Reactivity to Nonreactive Peripheral Blood Confers Both High Avidity and Tumor Gene Transfer of Tumor-Reactive TCR (2006) (0)
- TherapyImplications for Adoptive Cell Transfer Gastrointestinal Cancers and Melanoma: Infiltrating Visceral Metastases from Phenotype and Function of T Cells (2013) (0)
- Erratum to: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (2011) (0)
- Correction to: A Journey in Science: Immersion in the search for effective cancer immunotherapies (2021) (0)
- Functional genomics of systemic IL-2 administration in humans (2001) (0)
- Multiple Human Tumor-Associated Antigens Present Immunodominant Epitopes from Generated by Electrofusion Simultaneously Hybrids of Dendritic Cells and Tumor Cells (2003) (0)
- Suppressive Population of Mac-1 After Immunization : Induction of a T Lymphocytes + Apoptotic Death of CD 8 and (1998) (0)
- Study and characterization of mutated antigen specific T cells isolated from fresh tumor and peripheral lymphocytes in cancer patients (2015) (0)
- Molecules in the Context of MHC Class I and Class II Multiple Human Tumor-Associated Antigens Present Immunodominant Epitopes from Generated by Electrofusion Simultaneously Hybrids of Dendritic Cells and Tumor Cells (2003) (0)
- NOS1 overexpression by melanoma cells contributes to type I IFN alpha signal dysfunction in immune cells (2012) (0)
- Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. (2022) (0)
- This information is current as Occurring T Regulatory Cells T Helper Cells and Hindered by Naturally + Tumor/Self-Antigen Is Augmented by CD4 T Cell Immunity Against a + CD8 (2013) (0)
- Urokinase-type plasminogen activator inhibitors for the expression (1995) (0)
- Locally recurrent disease following combined modality treatment of high-grade soft tissue sarcomas (1984) (0)
- Memory T cells in the tumor-infiltrating lymphocytes for adoptive cell transfer therapy (2007) (0)
- T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma (2022) (0)
- Humoral immune response to chemically induced sarcomas. Abstr. (1976) (0)
- Recognize the Same Tumor Epitope Utilizing Distinct T-Cell Receptor Variable and Joining Regions Identification of MART-1-specific T-Cell Receptors : T Cells (2006) (0)
- Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma (2020) (0)
- Principles and practice of the biologic therapy of cancer ( third edition ) (2002) (0)
- Selective Rescue by Caspase Inhibition Tumor : Cells Following Activation by Specific Fas-Mediated Suicide of Tumor-Reactive T (1999) (0)
- USE OF DENDRITIC CELLS AND INTERLEUKIN-7 TO PROPAGATE ANTI-TUMOR MURINE CD4+ T CELLS FOR SUBSEQUENT ADOPTIVE THERAPY (1993) (0)
- PD-1 expression on peripheral blood lymphocytes enables direct enrichment of mutation-specific lymphocytes (VAC12P.1117) (2015) (0)
- In vitro and in vivo studies of human lymphocytes genetically engineered to express T cell receptors that recognize a p53 antigenic epitope (2008) (0)
- and normal B cells antigen receptor that recognizes murine CD19 can eradicate lymphoma Adoptive transfer of syngeneic T cells transduced with a chimeric (2013) (0)
- Patients Treated with CTLA-4 Blockade Antitumor Responses and Autoimmunity in Analysis of the Cellular Mechanism of (2005) (0)
This paper list is powered by the following services:
Other Resources About Steven Rosenberg
What Schools Are Affiliated With Steven Rosenberg?
Steven Rosenberg is affiliated with the following schools:
